View Filing Data

Balance (in shares) at Jun. 30, 2014

(21,378)

Balance at Jun. 30, 2014

$ 116,203

^[1]

5,878

(61)

(141,111)

(135,294)

75,422,773

2,809,950

Issuance of Common Stock upon exercise of employee and non-employee stock based awards

^[1]

Issuance of Common Stock upon exercise of employee and non-employee stock options, shares

34,898

Issuance of Convertible Preferred stock, net of issuance expenses

$ 24,712

Issuance of Convertible Preferred stock, net of issuance expenses, shares

9,321,019

Equity based compensation expenses to employees and non-employee consultants

2,956

Conversion of convertible preferred stock into ordinary shares

$ (140,915)

$ 3

140,912

140,915

Conversion of convertible preferred stock into ordinary shares, shares

(84,743,792)

28,247,923

Issuance of common stock in initial public offering, net of issuance expenses

$ 1

131,207

131,208

Issuance of common stock in initial public offering, net of issuance expenses, shares

8,050,000

Exercise of warrants into common stock

^[1]

6,115

$ 6,115

Exercise of warrants into common stock, shares

154,768

Change in accumulated other comprehensive loss related to foreign currency translation adjustments

(161)

$ (161)

Balance (in shares) at Jun. 30, 2015

21,121

Balance at Jun. 30, 2015

$ 4

^[1]

287,152

(222)

(119,990)

166,944

39,297,539

Issuance of Common Stock upon exercise of employee and non-employee stock based awards

^[1]

2,973

Issuance of Common Stock upon exercise of employee and non-employee stock options, shares

1,592,383

Equity based compensation expenses to employees and non-employee consultants

9,089

Change in accumulated other comprehensive loss related to foreign currency translation adjustments

493

Balance (in shares) at Jun. 30, 2016

76,609

Balance at Jun. 30, 2016

$ 4

299,214

271

(43,381)

256,108

40,889,922

Issuance of Common Stock upon exercise of employee and non-employee stock based awards

^[1]

349

Issuance of Common Stock upon exercise of employee and non-employee stock options, shares

286,150

Issuance of Common stock under employee stock purchase plan

^[1]

935

Issuance of Common stock under employee stock purchase plan, share

83,319

Equity based compensation expenses to employees and non-employee consultants

6,600

Change in accumulated other comprehensive loss related to foreign currency translation adjustments

(595)

Balance (in shares) at Dec. 31, 2016

25,381

Balance at Dec. 31, 2016

$ 4

$ 307,098

$ (324)

$ (18,000)

$ 288,778

41,259,391

[1]	Represents an amount less than $1.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Issuance of common stock in initial public offering, issuance expenses	$ 13,692
Series E Convertible Preferred Stock [Member]
Issuance of Convertible Preferred stock, issuance expenses	$ 288
Series D2 Convertible Preferred Stock [Member]
Issuance of Convertible Preferred stock, issuance expenses		$ 17
Series D3 Convertible Preferred Stock [Member]
Issuance of Convertible Preferred stock, issuance expenses		$ 9

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Cash flows provided by (used in) operating activities:
Net income (loss)	$ 25,381	$ 76,609	$ 21,121	$ (21,378)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, equipment and intangible assets	2,759	3,847	2,253	1,978
Amortization of premium on available-for-sale marketable securities	681	532
Stock-based compensation	6,600	9,089	2,956	1,082
Financial expenses (income), net related to term loan			(992)	431
Remeasurement of warrants to purchase convertible preferred stock			5,350	(53)
Capital loss from disposal of property			104
Interest expenses related to short term bank loan				44
Changes in assets and liabilities:
Inventories	14,022	(7,356)	(48,507)	(10,681)
Prepaid expenses and other accounts receivable	(367)	10,542	(19,563)	(7,409)
Trade receivables, net	1,555	(37,271)	(16,333)	(9,911)
Deferred tax assets, net	3,652	(6,380)
Trade payables	(14,464)	(32,200)	41,111	19,441
Employees and payroll accruals	2,996	3,278	1,668	1,726
Warranty obligations	7,183	19,313	13,698	7,803
Deferred revenues	1,335	8,578	3,989	(500)
Accrued expenses and other accounts payable	(1,999)	3,934	2,530	(418)
Lease incentive obligation	(236)	(88)	2,669
Net cash provided by (used in) operating activities	49,098	52,427	12,054	(17,845)
Cash flows from investing activities:
Purchase of property and equipment	(11,025)	(15,690)	(11,765)	(2,990)
Purchase of intangible assets	(600)	(800)
Decrease (increase) in restricted cash	31	2,711	(2,038)	(156)
Decrease (increase) in long-term lease deposit	(77)	103	(134)	(1)
Investment in available-for-sale marketable securities	(40,858)	(118,511)
Maturities of available-for-sale marketable securities	32,782	6,350
Net cash used in investing activities	(19,747)	(125,837)	(13,937)	(3,147)
Cash flows from financing activities:
Proceeds from short term bank loan			23,000	21,813
Repayment of short term bank loan			(36,326)	(12,447)
Repayments of term loan			(5,919)	(2,401)
Proceeds from issuance of Convertible Preferred stock, net
Proceeds from initial public offering, net			131,402
Issuance costs related to initial public offering		(194)
Proceeds from issuance of shares under stock purchase plan and upon exercise of options	1,284	2,973	84	51
Net cash provided by financing activities	1,284	2,779	136,953	17,676
Increase (decrease) in cash and cash equivalents	30,635	(70,631)	135,070	(3,316)
Cash and cash equivalents at the beginning of the period	74,032	144,750	9,754	13,142
Effect of exchange rate differences on cash and cash equivalents	16	(87)	(74)	(72)
Cash and cash equivalents at the end of the period	104,683	74,032	144,750	9,754
Supplemental disclosure of non-cash financing activities:
Deferred issuance costs related to initial public offering			194
Cashless exercise of warrants to purchase common stock			6,115
Supplemental disclosure of cash flow information:
Cash paid for interest			896	1,085
Cash paid for income taxes	1,103	1,178	4,040	92
Series D2 Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Convertible Preferred stock, net				669
Series D3 Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Convertible Preferred stock, net				9,991
Series E Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Convertible Preferred stock, net			$ 24,712

GENERAL

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1:-

GENERAL

SolarEdge Technologies, Inc. (the “Company”) and its subsidiaries design, develop, and sell an intelligent inverter solution designed to maximize power generation at the individual photovoltaic (“PV”) module level while lowering the cost of energy produced by the solar PV system and providing comprehensive and advanced safety features. The Company’s products consist mainly of (i) power optimizers designed to maximize energy throughput from each and every module through constant tracking of Maximum Power Point individually per module, (ii) inverters which invert direct current (DC) from the PV module to alternating current (AC) and (iii) a related cloud-based monitoring platform, that collects and processes information from the power optimizers and inverters of a solar PV system to enable customers and system owners as applicable, to monitor and manage the solar PV systems. In addition, the Company has a storage solution that is used to increase energy independence and maximize self-consumption for homeowners by utilizing a battery that is sold separately by third party manufacturers, to store and supply power as needed (the “StorEdge solution”). The StorEdge solution is designed to provide smart energy functions such as maximizing self-consumption, Time-of-Use programming for desired hours of the day, and home energy backup solutions.

The Company and its subsidiaries sells its products worldwide directly to large solar installers and engineering, procurement and construction firms (“EPCs”), as well as through large distributors and electrical equipment wholesalers to smaller solar installers.

The Company was incorporated in Delaware in August 2006 and began commercial sale of its products in January 2010.

Basis of presentation:

Effective December 31, 2016, the Company changed its fiscal year end form June 30 to December 31. This change is being made in order to align the Company’s fiscal year end with other companies within the industry. As a result of this change, the consolidated financial statements include presentation of the six month transition period from July 1, 2016 through December 31, 2016. The Company refers to the period beginning July 1, 2015 and ending June 30, 2016 as “fiscal 2016”, the period beginning July 1, 2014 and ending June 30, 2015 as “fiscal 2015” and the period beginning July 1, 2013 and ending June 30, 2014 as “fiscal 2014”.

Initial Public Offering:

On March 31, 2015, the Company closed its initial public offering (“IPO”) whereby 8,050,000 shares of common stock were sold by the Company to the public (inclusive of 1,050,000 shares of common stock pursuant to the full exercise of an overallotment option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were approximately $131,208, net of underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all shares of the Company’s outstanding convertible preferred stock automatically converted into 28,247,923 shares of common stock, and outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock (See Note 10).

As of December 31, 2016, June 30, 2016 and 2015, the Company had one, three and one major customers (customers with attributable revenues that represents more than 10% of total revenues) that accounted for approximately 11.2%, 32.5% and 24.6% of the Company’s consolidated revenues, respectively (see Note 20).

The Company depends on two contract manufacturers and several limited or single source component suppliers. Reliance on these vendors makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. Two vendors collectively accounted for 61%, 69% and 79% of the Company’s total trade payables as of December 31, 2016, June 30, 2016 and 2015, respectively.

The Company has the right to offset its payables to one of its contract manufacturers against vendor non-trade receivables. As of December 31, 2016, a total of $2,008 of these receivables met the criteria for net recognition and were offset against the corresponding accounts payable balances for this contract manufacturer in the accompanying Consolidated Balance Sheets.

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”).

Principles of consolidation:

The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances including profits from intercompany sales not yet realized outside the Company have been eliminated upon consolidation.

Use of estimates:

The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to warranty obligation, inventory valuation, contingencies, share-based compensation cost, marketable securities, deferred tax assets and libilities, intangible assets as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Financial statements in U.S. dollars:

The functional currency of the Company and its Israeli subsidiary is the U.S. dollar, as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. The Company’s and its Israeli subsidiary’s operations are currently primarily conducted in Israel and a significant portion of its expenses are currently paid in U.S. dollars. Financing activities including loans and cash investments, are mainly made in U.S. dollars.

Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are translated into U.S. dollars in accordance with Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 830 (“Foreign Currency Matters”). All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.

The financial statements of other Company’s subsidiaries whose functional currency is other than the U.S. dollar, have been translated into U.S dollars. Assets and liabilities have been translated using the exchange rates in effect on the balance sheet date. Statements of operations amounts have been translated using the average exchange rate for the relevant periods.

The resulting translation adjustments are reported as a component of stockholders’ equity (deficiency) in accumulated other comprehensive income (loss).

Accumulated other comprehensive loss related to foreign currency translation adjustments, net amounted to $207, $29 and $222 as of December 31, 2016, June 30, 2016 and 2015, respectively.

Basic and Diluted Net Earnings (Loss) Per Share:

Basic net earnings (loss) per share is computed by dividing the net earnings (loss) by the weighted-average number of shares of common stock outstanding during the period.

Diluted net earnings (loss) per share is computed by giving effect to all potential shares of common stock, including stock options and convertible preferred stock, to the extent dilutive, all in accordance with ASC No. 260, "Earnings Per Share."

The total weighted average number of shares related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock, excluded from the calculation of diluted net earnings (loss) per share due to their anti-dilutive effect was 374,156, 16,208 , 20,565,747 and 25,234,818 for the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014, respectively.

Basic and diluted earnings (loss) per share is presented in conformity with the two-class method for participating securities for the periods prior to their conversion. Under this method the earnings per share for each class of shares are calculated assuming 100% of the Company’s earnings are distributed as dividends to each class of shares based on their contractual rights. In addition, since all classes other than common stock do not participate in losses, for the year ended June 30, 2014 these shares are not included in the computation of basic loss per share.

For the year ended June 30, 2014, basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following table presents the computation of basic and diluted net earnings (loss) per share for the periods presented (in thousands, except share and per share data):

	Six months Ended December 31,		Year ended June 30,
	2016		2016		2015			2014
Net basic earnings (loss) per share of common stock:
Numerator:
Net income (loss)		25,381		76,609		21,121			(21,378	)
Dividends accumulated for the period		-		-		(17,550	)		-
Net income (loss) available to shareholders of common stock		25,381		76,609		3,571			(21,378	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic		41,026,926		39,987,935		11,902,911			2,798,894

Net diluted earnings (loss) per share of common stock:
Numerator:
Net income (loss)		25,381		76,609		21,121			(21,378	)
Dividends accumulated for the period		-		-		(16,971	)		-
Net income (loss) available to shareholders of common stock		25,381		76,609		4,150			(21,378	)

Denominator:
Shares used in computing net earnings per share of common stock, basic		41,026,926		39,987,935		11,902,911			2,798,894
Effect of stock-based awards		2,812,416		4,388,140		3,366,537			-
Shares used in computing net earnings (loss) per share of common stock, diluted		43,839,342		44,376,075		15,269,448			2,798,894

Cash and cash equivalents:

Cash equivalents are short-term, highly liquid investments that are readily convertible to cash, with original maturities of three months or less at the date acquired.

Marketable Securities:

Marketable securities consist of corporate and governmental bonds. The Company determines the appropriate classification of marketable securities at the time of purchase and re-evaluates such designation at each balance sheet date. In accordance with FASB ASC No. 320 “Investments - Debt and Equity Securities”, the Company classifies marketable securities as available-for-sale. Available-for-sale securities are stated at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), a separate component of stockholders’ equity, net of taxes.

Realized gains and losses on sales of marketable securities, as determined on a specific identification basis, are included in financial income (expenses), net. The amortized cost of marketable securities is adjusted for amortization of premium and accretion of discount to maturity, both of which, together with interest, are included in financial income (expenses), net.

The Company classifies its marketable debt securities as either short-term or long-term based on each instrument’s underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term.

The Company recognizes an impairment charge when a decline in the fair value of its investments in debt securities below the cost basis of such securities is judged to be other-than-temporary. Factors considered in making such a determination include the duration and severity of the impairment, the reason for the decline in value, the potential recovery period and the Company’s intent to sell, including whether it is more likely than not that the Company will be required to sell the investment before recovery of cost basis. If the Company does not intend to sell the security or it is not more likely than not that it will be required to sell the security before it recovers in value, the Company must estimate the net present value of cash flows expected to be collected. If the amortized cost exceeds the net present value of cash flows, such excess is considered a credit loss and an other-than-temporary impairment has occurred. For securities that are deemed other-than-temporarily impaired (“OTTI”), the amount of impairment is recognized in the statement of operations and is limited to the amount related to credit losses, while impairment related to other factors is recognized in other comprehensive income (loss). The Company did not recognize OTTI on its marketable securities during the six months ended December 31, 2016 and the year ended on June 30, 2016.

Restricted cash:

Restricted cash is primarily invested in short-term bank deposits, which are primarily used to guarantee a letter of credit which has been issued to one of the Company’s major vendors, to the Company’s landlords for its office leases and as security for the Company’s credit cards.

Inventories:

Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.

The Company periodically evaluates the quantities on hand relative to historical, current and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its market value. Cost of finished goods and raw materials is determined using the moving average cost method.

Property, equipment and intangible assets:

Property and equipment:

Property and equipment are stated at cost, net of accumulated depreciation. Machinery & equipment in progress is the construction or development of property and equipment that have not yet been placed in service for the Company's intended use. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets, at the following rates:

		%

Computers and peripheral equipment		20 – 33 (mainly 33)
Office furniture and equipment		7 – 15 (mainly 7)
Machinery & equipment		7 – 33 (mainly 20)
Laboratory equipment		15
Vehicles		15
Leasehold improvements		over the shorter of the lease term or useful economic life

Intangible assets:

Intangible assets are stated at cost, net of accumulated amortization. Amortization is calculated by the straight-line method over the estimated useful lives of the assets (see Note 7).

Impairment of long-lived assets:

The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360 (“Property, Plants and Equipment”), whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset (or asset group) to the future undiscounted cash flows expected to be generated by the assets (or asset group).

If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. For the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014, no impairment losses have been identified.

k. Severance pay:

Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. The employees of the Company’s Israeli subsidiary have elected to be included under section 14 of the Severance Pay Law, 1963, under which these employees are entitled only to monthly deposits made in their name with insurance companies, at a rate of 8.33% of their monthly salary. These payments cause the Company to be released from any future obligation under the Israeli Severance Pay Law to make severance payments in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.

For the six months ended December 31, 2016, and the years ended June 30, 2016, 2015 and 2014, the Company recorded $1,131, $1,761, $1,273 and $1,109, severance expenses, respectively.

Revenue recognition:

The Company and its subsidiaries generate their revenues mainly from the sale of power optimizers, inverters and cloud-based monitoring services, to distributors, installers and PV module manufacturers.

Revenues from product sales and related services are recognized in accordance with ASC 605 (“Revenue Recognition”), when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, collectability is reasonably assured and no significant obligations remain.

Persuasive evidence of an arrangement exists. The Company’s customers mainly consist of distributors and installers (the “Customers”). The Company’s sales arrangements with Customers are pursuant to written documentation, either a written contract or purchase order. The actual documentation used is dependent on the business practice with each Customer. Therefore, the Company determines that persuasive evidence of an arrangement exists with respect to a Customer when it has a written contract, or a binding purchase order from the Customer.

Delivery has occurred. Each item of written documentation relating to a sale arrangement that is agreed upon with the Customer specifically sets forth when risk of loss and title are being transferred (based on the agreed International Commercial terms, or “INCOTERMS”). Unless a different written arrangement with the Customer exists, the Company determines that risk of loss and title are transferred to the Customer when the applicable INCOTERMS are satisfied and thus delivery of its products has occurred.

The fee is fixed or determinable. The Company does not provide any price protection, stock rotation and/or right of return and thus the Company considers all the Customers as end-users and the fee is considered fixed and determinable upon execution of the written documentation with the Customers.

Additionally, payments that are due within the normal course of the Company’s credit terms, which are currently no more than three months from the delivery date, are deemed to be fixed and determinable. Fees and arrangements with payment terms extending beyond customary payment terms are considered not to be fixed or determinable, in which case revenues are deferred and recognized when payments become due, provided that all other revenue recognition criteria have been met.

Collectability is reasonably assured. The Company determines whether collectability is reasonably assured on a Customer-by-Customer basis pursuant to its credit review policy. The Company typically sells to Customers with whom it has a long-term business relationship and a history of successful collection. For a new Customer, or when an existing Customer substantially expands its commitments, the Company evaluates the Customer’s financial position, the number of years the Customer has been in business, the history of collection with the Customer and the Customer’s ability to pay and typically assigns a credit limit based on that review.

Provisions for rebates, sales incentives, and discounts to customers are accounted for as reductions in revenue in the same period the related sales are recorded.

The Company increases a credit limit only after it has established a successful collection history with the Customer. If the Company determines at any time that collectability is not reasonably assured under a particular arrangement based upon its credit review process, the Customer’s payment history or information that comes to light about a Customer’s financial position, it recognizes revenue under that arrangement as Customer payments are actually received.

Revenues related to cloud-based monitoring and other services are recognized ratably on a straight-line basis over the estimated service period.

For multiple-element arrangements, the Company allocates revenue to all deliverables based on their relative selling prices. In such circumstances, the Company uses a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“ESP”).

VSOE generally exists only when the Company sells the deliverable separately and is the price actually charged by the Company for that deliverable. ESPs reflect the Company’s best estimates of what the selling prices of elements would be if they were sold regularly on a stand-alone basis. The Company has allocated revenue between its deliverables based on their relative selling prices. Because the Company has neither VSOE nor TPE for its deliverables, the allocation of revenue has been based on the Company’s ESPs. Amounts allocated to the delivered elements are recognized at the time of sale provided the other conditions for revenue recognition have been met.

The Company’s process for determining its ESP considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable.

Key factors considered by the Company in developing the ESPs for its products include prices charged by the Company for similar offerings, the Company’s historical pricing practices and product-specific business objectives.

Deferred revenues consist of deferred cloud-based monitoring services, other services, advance payments received from Customers for the Company’s products and warranty extensions, and are classified as short-term and long-term deferred revenues based on the period in which revenues are expected to be recognized.

Cost of revenues:

Cost of revenues sold includes the following: product costs consisting of purchases from contract manufacturers and other suppliers, indirect manufacturing, support, warranty expenses and changes in warranty provision, provision for losses related to slow moving and dead inventory, personnel and logistics costs and royalty expense payments to the Office of the Chief Scientist of Israel (see Note 2q).

Shipping and handling costs:

Shipping and handling costs, which amounted to $8,131, $21,922, $26,931 and $14,066 for the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014, respectively, are included in cost of revenues in the consolidated statements of operations. Shipping and handling costs include all costs associated with the distribution of finished products from the Company’s point of selling directly to its Customers.

Warranty obligations:

The Company’s products include a 10-year limited warranty for StorEdge products, a minimum 12-year limited warranty for inverters and a 25-year limited warranty for power optimizers. In certain cases, the Company provides extended warranties for inverters that bring the warranty period up to 25 years. The Company maintains reserves to cover the expected costs that could result from these warranties. The potential liability is generally in the form of product replacement and associated costs. Warranty reserves are based on the Company’s best estimate of such costs and are included in cost of revenues. The reserve for the related warranty expenses is based on various factors including assumptions about the frequency of warranty claims on product failures, derived from results of accelerated lab testing, field monitoring, analysis of the history of product failures and the Company’s reliability estimates.

The Company has established a reliability measurement system based on the units’ estimated mean time between failure, or MTBF, a metric that equates to a steady-state failure rate per year for each products generation. The MTBF predicts the expected failure rate of each product within the company's products installed base during the expected product warranted lifetime.

The Company performs accelerated life cycle testing, which simulates the service life of the product in a short period of time.

The accelerated life cycle tests incorporate test methodologies derived from standard tests used by solar module vendors to evaluate the period over which solar modules wear out. Corresponding replacement costs are updated periodically to reflect changes in the Company’s actual and estimated production costs for its products, rate of usage of refurbished units as a replacement of faulty units and other costs related to logistic and subcontractors services associated with the replacement.

In addition, through the collection of actual failure statistics, the Company has identified several additional failure causes that are not included in the MTBF calculations. Such causes, which mostly consist of design errors, workmanship errors caused during the manufacturing process and, to a lesser extent, replacement of non-faulty units by installers, are generating additional replacement costs to the replacement costs projected under the MTBF model. The Company identified each of those causes, its failure pattern and the relative ratio compared to the pattern of malfunctions identified under the MTBF and accrued additional provisions for the occurrence of such malfunctioning. The Company evaluates the continuation of these occurrences and the appearance of potential additional malfunctioning cases beyond the MTBF pattern and accrues additional expenses accordingly.

Warranty obligations are classified as short-term and long-term warranty obligations based on the period in which the warranty is expected to be claimed.

Royalty-bearing grants from the Binational Industrial Research and Development Foundation:

Royalty-bearing grants from the Binational Industrial Research and Development Foundation (“BIRD-F”) for funding of approved research and development projects are recognized, as a deduction from research and development expenses, at the time the Company is entitled to such grants (see Note 14c).

No grants were recorded in the six months ended December 31, 2016 and in the years ended June 30, 2016, 2015 and 2014.

Government grants:

Government grants received by the Company’s Israeli subsidiary relating to categories of operating expenditures are credited to the consolidated statements of operations during the period in which the expenditure to which they relate is charged. Royalty bearing grants from the Israeli Office of the Chief Scientist (“OCS”) for funding certain approved research and development projects are recognized at the time when the Company’s Israeli subsidiary is entitled to such grants, on the basis of the related costs incurred, and are included as a deduction from research and development expenses.

The Company recorded grants in the amount of $763 and $275 for the year ended June 30, 2015 and 2014, respectively, which was deducted from research and development expenses.

No grants were recorded for the six months ended December 31, 2016 and for the year ended June 30, 2016.

Research and development costs:

Research and development costs, net of grants received, are charged to the consolidated statement of operations as incurred.

Concentrations of credit risks:

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, trade receivables, other accounts receivable and marketable securities.

Cash and cash equivalents are mainly invested in major banks in the U.S., Israel, Australia and in Germany. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.

The Company’s marketable securities consist of corporate and governmental bonds.

The Company's marketable securities include investments in highly rated debentures (mainly of U.S., Canada, Australia and other Europan countries) corporations and governmental bonds. The financial institutions that hold the Company's marketable securities are major U.S. financial institutions, located in the United States. Management believes that the Company's marketable securities portfolio is a diverse portfolio of highly-rated securities and the Company's investment policy limits the amount the Company may invest in each issuer, and accordingly, management believes that minimal credit risk exists from geographic or credit concentration with respect to these securities.

As of December 31, 2016 and June 30, 2016, the amortized cost of the Company’s marketable securities was $118,950 and $111,514, respectively, and their stated market value was $118,727 and $111,609, respectively, representing a net unrealized loss of $223 and a net unrealized gain of $95 , respectively.

The trade receivables of the Company are derived from sales to Customers located primarily in North America, Europe and Australia.

The Company generally does not require collateral however, in certain circumstances, the Company may require letters of credit, other collateral or additional guarantees.

An allowance for doubtful accounts is determined with respect to specific debts that are doubtful of collection. The Company accrued $226, $235 and $13 as allowance for doubtful accounts as of December 31, 2016, June 30, 2016 and 2015, respectively.

In addition, an accrual for rebates is allocated to specific debts. The Company accrued $9,089, $4,294 and $659 for rebates as of December 31, 2016, June 30, 2016 and 2015, respectively.

As of December 31, 2016, June 30, 2016 and 2015, the Company had one, two and one major customers (customers with a balance that represents more than 10% of total trade receivables) which accounted in the aggregate for approximately 20.2%, 34.4% and 30.0%, respectively, of the Company’s consolidated trade receivables.

The Company and its subsidiaries have no off-balance sheet concentration of credit risk except for certain derivative instruments as mentioned below.

t. Fair value of financial instruments:

The following methods and assumptions were used by the Company in estimating the fair value of its financial instruments:

The carrying value of cash and cash equivalents, restricted cash, trade receivables, prepaid expenses and other accounts receivable, short term bank loan, trade payables, employees and payroll accruals and accrued expenses and other accounts payable approximate their fair values due to the short-term maturities of such instruments.

Assets measured at fair value on a recurring basis as of December 31, 2016 and June 30, 2016 are comprised of foreign currency derivative contracts and marketable securities. (see Note 4)

Assets measured at fair value on a recurring basis as of June 30, 2015 are comprised of foreign currency forward contracts.

The Company applies ASC 820 (“Fair Value Measurements and Disclosures”), with respect to fair value measurements of all financial assets and liabilities.

Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

A three-tiered fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

Level 1-

Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2-

Include other inputs that are directly or indirectly observable in the marketplace.

Level 3-

Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Warrants to Purchase Convertible Preferred Stock:

The Company accounts for freestanding warrants to purchase shares of its convertible preferred stock as a liability on the balance sheets at fair value. The warrants to purchase convertible preferred stock are recorded as a liability because of a provision calling for minimum proceeds upon or after an “Exit Event”, as described in Note 10.

The fair value of warrants to purchase convertible preferred stock on the issuance date and on subsequent reporting dates was determined using a hybrid method utilizing the assumptions noted below. The fair value of the underlying preferred stock price was determined by the board of directors considering, among others, third party valuations. The valuation of the Company was performed using the hybrid method, a hybrid between the probability-weighted estimated return method (“PWERM”) and Option Pricing Method (“OPM”) estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one or more of those scenarios. The OPM was used to allocate the Company’s equity value between the preferred stock, common stock and warrants in a scenario of other liquidation events.

The expected terms of the warrants were based on the remaining contractual expiration period. The expected share price volatility for the shares was determined by examining the historical volatilities of a group of the Company’s industry peers as there was insufficient trading history of the Company’s shares. The risk-free interest rate was calculated using the average of the published interest rates for U.S. Treasury zero-coupon issues with maturities that approximate the expected term.

The dividend yield assumption was zero as there is no history of dividend payments and the Company does not expect to pay any dividends in the foreseeable future.

The following assumptions were used to estimate the value of the warrants to purchase convertible preferred stock:

		June 30,
		2014

Expected volatility		45.0%
Risk-free rate		0.09%
Dividend yield		0%
Expected term (in years)		1.21

The warrants to purchase convertible preferred stock were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized as a component of financial expenses, net, on the statements of operations.

The change in the fair value of warrants to purchase convertible preferred stock is summarized below:

	Balance at beginning of period		Issuance of warrants to purchase preferred stock		Exercise of warrants to purchase common stock (*)			Change in fair value			Balance at end of period

June 30, 2015	$	765	$	-	$	(6,115	)	$	5,350		$	-
June 30, 2014	$	818	$	-	$	-		$	(53	)	$	765

(*)

Upon the closing of the IPO, all outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock (See Note 1c).

On June 18, 2015 the warrants were redeemed in a cashless exercise into 154,768 common shares. Immediately before the cashless exercise the warrants were remeasured to fair value based on their intrinsic value which amounted to $6,115 (see Note 10).

Accounting for stock-based compensation:

The Company accounts for stock-based compensation in accordance with ASC 718 (“Compensation-Stock Compensation”). ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.

In March 2016, the FASB issued Accounting Standards Update No. 2016-09, “Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company has early adopted this guidance.

The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures (pursuant to the adoption of ASU 2016-09, the Company made a policy election to estimate the number of awards that are expected to vest).

The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-option awards and Employee Stock Purchase Plan. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying common stock, expected stock price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with SAB No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has not declared or paid any dividends on its common stock and does not expect to pay any dividends in the foreseeable future.

The fair value of the shares of common stock underlying the stock options has historically been determined by the Company’s management and approved by the board of directors. Because until March 31, 2015, there was no public market for the Company’s common stock, the Company’s management determined the fair value of the common stock by using, among other factors, third party valuations at the time of grant of the option by considering a number of objective and subjective factors, including data from other comparable companies, issuance of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and general and industry specific economic outlook.

The fair value of the underlying common stock was determined by the management until such time as the Company’s common stock is listed on an established stock exchange or national market system. The Company’s management determined the value of the shares of common stock based on valuations performed using the OPM for the year ended June 30, 2014 and for the period from July 1, 2014 and up to March 31, 2015. The common stock of the Company has been publicly traded since March 31, 2015.

Since the distributions and participation rights to security holders until March 31, 2015 are different in a sale/liquidation scenario versus an IPO, the valuation of the Company's equity was performed using a discounted cash flow (DCF) model or a new investment round by external investors. The allocation of the Company's equity value between the convertible preferred stock, common stock and warrants was performed using a hybrid method between the PWERM and OPM estimating the probability-weighted value across multiple scenarios for liquidation events other than an IPO.

Before the per share value was determined, a discount for lack of marketability and a voting right differential was applied, as applicable, to the common stock.

The fair value for options granted to employees and executive directors and Employee Stock Purchase Plan in the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions:

	Six months ended December 31,	Year ended June 30,
	2016	2016	2015	2014
Employee Stock Options
Risk-free interest	1.28% - 1.34%	1.39% - 1.97%	1.39% - 2.06%	1.62% - 1.94%
Dividend yields	0%	0%	0%	0%
Volatility	55.33% - 55.34%	55.45%-56.03%	46.5%-55.1%	46.3%-55.8%
Expected option term in years	6.06	5.50-6.11	5.50-6.27	6.02-6.27
Estimated forfeiture rate	0%	10.3%	12.5%-18.7%	14.0%

Employee Stock Purchase Plan
Risk-free interest	0.60%	0.40%	-	-
Dividend yields	0%	0%	-	-
Volatility	48.08%	62.84%	-	-
Expected term	6 months	6 months	-	-

The following table set forth the parameters used in computation of the options compensation to non-employee consultants in the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014, using a Black-Scholes-Merton option pricing model with the following assumptions:

	Six Months ended December 31,	Year ended June 30,
	2016	2016	2015	2014

Risk-free interest	1.16% - 2.45%	1.15%-2.21%	1.59%-2.58%	2.26%-2.75%
Dividend yields	0%	0%	0%	0%
Volatility	55.33% - 58.57%	55.37%-55.75%	45.5%-56.2%	45.0%-55.8%
Contractual life in years	6 - 10	6.4-10	7.4-10	8.3 - 10

The Company recognizes compensation expenses for the value of its restricted stock unit (“RSU”) awards, based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. The fair value of each RSU is the market value as determined by the closing price of the common stock on the day of grant.

Income taxes:

The Company and its subsidiaries account for income taxes in accordance with ASC 740, “Income Taxes.” ASC 740 prescribes the use of the liability method, whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse.

The Company and its subsidiaries provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

The Company accounts for uncertain tax positions in accordance with ASC 740. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.

The company record reserves for uncertain tax positions to the extent it is more likely than not that the tax position will be sustained on audit, based on the technical merits of the position.

Derivative financial instruments:

The Company accounts for derivatives and hedging based on ASC 815 (“Derivatives and Hedging”). ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship.

To protect against the increase in value of forecasted foreign currency cash flows resulting from salary and lease payments of its Israeli facilities denominated in the Israeli currency, the New Israeli Shekel (“NIS”), during the six months ended December 31, 2016 and the year ended June 30, 2016, the Company instituted a foreign currency cash flow hedging program. The Company hedges portions of the anticipated payroll and lease payments denominated in NIS for a period of one to twelve months with hedging contracts. These hedging contracts are designated as cash flow hedges, as defined by ASC 815 and are all effective hedges.

In accordance with ASC 815, for derivative instruments that are designated and qualify as a cash flow hedge (i.e. hedging the exposure to variability in expected future cash flows that is attributable to a particular risk), the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Any gain or loss on a derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item is recognized in current earnings during the period of change.

In addition to the above mentioned cash flow hedges transactions, the Company also entered into derivative instrument arrangements to hedge the Company’s exposure to currencies other than the U.S. dollar. These derivative instruments are not designated as cash flows hedges, as defined by ASC 815, and therefore all gains and losses, resulting from fair value remeasurement, were recorded immediately in the statement of operations, as financial income (expenses).

As of December 31, 2016, the Company entered into forward contracts to sell U.S. dollars for NIS in the amount of $5,098. These hedging contracts do not contain any credit-risk-related contingency features. See Note 4 for information on the fair value of these hedging contracts.

As of December 31, 2016, the Company had no derivative instruments that are not designated as cash flows hedges.

As of June 30, 2016, the Company entered into forward contracts and put and call options to sell U.S. dollars for NIS and Euros for U.S. dollars in the amount of $17,693 and €30,000, respectively. These hedging contracts do not contain any credit-risk-related contingency features.

The fair value of derivative assets as of December 31, 2016 was $19, which was recorded in other accounts receivable and prepaid expenses in the consolidated balance sheets (see Note 13).

The fair value of derivative assets and derivative liabilities as of June 30, 2016 was $504 and $23, respectively, which was recorded at net amount in other accounts receivable and prepaid expenses in the consolidated balance sheets.

Comprehensive income (loss):

The Company reports comprehensive income (loss) in accordance with ASC 220 (“Comprehensive Income”). ASC 220 establishes standards for the reporting and presentation of comprehensive income and its components in a full set of general purpose financial statements.

Total comprehensive income (loss) and the components of accumulated other comprehensive income (loss) are presented in the consolidated statements of stockholders’ equity (deficiency). Accumulated other comprehensive income (loss) consists of foreign currency translation effects, unrealized gains and losses on available-for-sale marketable securities and hedging contracts.

The impact of recently issued accounting standards still not effective for the Company as of December 31, 2016 is as follows:

In May 2014, the FASB issued a new standard related to revenue recognition. Under the new standard, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has recently issued several amendments to the standard, including clarification on identifying performance obligations.

The guidance permits two methods of modification: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company currently anticipates adopting the standard using the modified retrospective method rather than full retrospective method.

The new standard will be effective for the Company beginning January 1, 2018, and adoption as of the original effective date of January 1, 2017 is permitted. The Company will adopt the new standard as of January 1, 2018.

The Company has made progress toward completing its evaluation of the potential changes from adopting this new standard on its financial reporting and disclosures. The Company has evaluated the impact of the standard on all of its revenue streams and most of its contracts. The Company expects to complete the contract evaluations and validate the results during the first half of 2017. During this time frame and the remainder of 2017, the Company will also draft a new accounting policies and evaluate the new disclosure requirements. The Company formed an implementation work group and expects to complete the evaluation of the impact of the accounting and disclosure changes on its business processes, controls and systems throughout 2017, design any changes to such business processes, controls and systems, and implement the changes before the end of 2017.

Under the new standard, an entity recognizes revenue when or as it satisfies a performance obligation by transferring a good or service to the customer, either at a point in time or over time. The Company expects to continue to recognize most of its revenue at a point in time upon delivery of its products. Based on its current analysis the most significant effect, if any, will be related to certain services that may no longer be considered as a distinct performance obligations separate from the main revenue products.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact that adopting this new accounting standard will have on its consolidated financial statements, footnote disclosures and employee benefit plans’ accounting.

In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18), which requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance will be effective for the Company in the first quarter of 2018 and early adoption is permitted. The Company is still evaluating the effect that this guidance will have on its consolidated financial statements and related disclosures.

MARKETABLE SECURITIES

12 Months Ended

Dec. 31, 2016

Marketable Securities [Abstract]

MARKETABLE SECURITIES

NOTE 3:-

MARKETABLE SECURITIES

The following is a summary of available-for-sale marketable securities at December 31, 2016:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Corporate bonds	$	111,188	$	23	$	(213	)	$	110,998
Governmental bonds	$	7,762		-	$	(33	)	$	7,729

	$	118,950	$	23	$	(246	)	$	118,727

The following is a summary of available-for-sale marketable securities at June 30, 2016:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Corporate bonds	$	103,494	$	136	$	(42	)	$	103,588
Governmental bonds	$	8,020	$	7	$	(6	)	$	8,021

	$	111,514	$	143	$	(48	)	$	111,609

As of June 30, 2015, the Company had no investments in marketable securities.

The amortized cost of available-for-sale marketable securities at December 31, 2016, by contractual maturities, is shown below:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Due in one year or less	$	74,511	$	20	$	(66	)	$	74,465
Due after one year to two years	$	44,439	$	3	$	(180	)	$	44,262

	$	118,950	$	23	$	(246	)	$	118,727

The amortized cost of available-for-sale marketable securities at June 30, 2016, by contractual maturities, is shown below:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Due in one year or less	$	59,124	$	50	$	(11	)	$	59,163
Due after one year to two years	$	52,390	$	93	$	(37	)	$	52,446

	$	111,514	$	143	$	(48	)	$	111,609

As of December 31, 2016 and June 30, 2016, management believes the impairments are not other than temporary and therefore the impairment losses were recorded in accumulated other comprehensive income (loss). The Company has no intent to sell these securities and it is more likely than not that the Company will not be required to sell these securities prior to the recovery of the entire amortized cost basis.

Proceeds from maturity of available-for-sale marketable securities during the six months ended December 31, 2016 and the year ended June 30, 2016 were $32,782 and $6,350, respectively. The Company had no proceeds from sales of available-for-sale marketable securities during the six months ended December 31, 2016 and the year ended June 30, 2016, therefore no realized gains or losses from the sale of available-for sale marketable securities were recognized. The Company determines realized gains or losses on the sale of available-for-sale marketable securities based on a specific identification method.

The entire disclosure for investments in certain debt and equity securities.

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2016

Fair Value Measurements

FAIR VALUE MEASUREMENTS

NOTE 4:-

FAIR VALUE MEASUREMENTS

In accordance with ASC 820, the Company measures its cash equivalents, foreign currency derivative contracts and marketable securities, at fair value using the market approach valuation technique. Cash equivalents and marketable securities are classified within Level 1 or Level 2. This is because these assets are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. Foreign currency derivative contracts are classified within the Level 2 value hierarchy, as the valuation inputs are based on quoted prices and market observable data of similar instruments.

The following table sets forth the Company’s assets that were measured at fair value as of December 31, 2016 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	December 31, 2016		Level 1		Level 2		Level 3

Cash equivalents:
Money market mutual funds	$	6,510	$	6,510		-		-

Derivative instruments asset	$	19		-	$	19		-

Short-term marketable securities:
Corporate bonds	$	71,719		-	$	71,719		-
Governmental bonds	$	2,746		-	$	2,746		-

Long-term marketable securities:
Corporate bonds	$	39,279		-	$	39,279		-
Governmental bonds	$	4,983		-	$	4,983		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2016 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2016		Level 1		Level 2		Level 3

Cash equivalents:
Money market mutual funds	$	13,373	$	13,373		-		-

Derivative instruments asset	$	481		-	$	481		-

Short-term marketable securities:
Corporate bonds	$	57,158		-	$	57,158		-
Governmental bonds	$	2,005		-	$	2,005		-

Long-term marketable securities:
Corporate bonds	$	46,430		-	$	46,430		-
Governmental bonds	$	6,016		-	$	6,016		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2015 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2015		Level 1		Level 2		Level 3

Derivative instruments asset	$	859		-	$	859		-

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

PREPAID EXPENSES AND OTHER ACCOUNTS RECEIVABLE

12 Months Ended

Dec. 31, 2016

PREPAID EXPENSES AND OTHER ACCOUNTS RECEIVABLE

NOTE 5:-

PREPAID EXPENSES AND OTHER ACCOUNTS RECEIVABLE

	December 31,		June 30,
	2016		2016		2015

Vendor non-trade receivables (*)	$	15,209	$	15,375	$	24,814
Government authorities		2,585		2,727		3,729
OCS		-		-		249
Prepaid expenses and other		3,534		2,756		2,994
Foreign currency derivative contracts		19		482		859

	$	21,347	$	21,340	$	32,645

(*) Vendor non-trade receivables related to contract manufacturers derive from the sale of components to manufacturing vendors who manufacture products for the Company. The Company purchases these components directly from suppliers. The Company does not reflect the sale of these components in revenues (see also Note 14e).

INVENTORIES

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 6:-

INVENTORIES

	December 31,		June 30,
	2016		2016		2015

Raw materials	$	10,053	$	9,805	$	14,405
Finished goods		57,310		71,745		59,545

	$	67,363	$	81,550	$	73,950

The Company recorded inventory write-downs of $113, $2,539, $992 and $1,131 for the six months ended on December 31, 2016 and for the years ended June 30, 2016, 2015 and 2014, respectively.

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS

NOTE 7:-

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS

Property and equipment:

	December 31,		June 30,
	2016		2016		2015

Cost:

Computers and peripheral equipment	$	6,053	$	5,190	$	3,139
Office furniture and equipment		1,505		1,289		779
Laboratory and testing equipment		9,589		8,590		7,205
Machinery and equipment		26,285		18,433		6,936
Leasehold improvements		5,898		5,450		4,047
Vehicles		13		13		13

		49,343		38,965		22,119

Less - accumulated depreciation		13,221		11,134		7,402

Depreciated cost	$	36,122	$	27,831	$	14,717

Property in progress under construction and development with a cost basis of $10,698, $5,519 and $1,765 was included in Machinery and equipment as of December 31, 2016, June 30, 2016 and 2015, respectively.

Depreciation expenses for the six months ended December 31, 2016 and for the years ended June 30, 2016, 2015 and 2014 were $2,702, $3,763, $2,253 and $1,978, respectively.

Intangible assets:

On March 9, 2015, the Company and Beacon Power LLC, a Delaware limited liability company (“Beacon”) entered into a patent purchase agreement pursuant to which the Company agreed to purchase all rights in the patents. In July 2015, the Company completed the purchase of the patents for $800.

In October 2016 the Company and Accurate Solar Power, LLC, a limited liability corporation, entered into a patent purchase agreement, under which the Company agreed to purchase certain patents, provisional patent applications and pending patent applications. The Company completed the purchase in return for total consideration of $600.

Intangible assets include an acquired patents with an original cost of $1,400 and $800 as of December 31, 2016 and June 30, 2016, respectively, and accumulated amortization of $141 and $84 as of December 31, 2016 and June 30, 2016, respectively. The patents are amortized over a 10 years period.

Amortization expenses for the six months ended December 31, 2016 and for year ended June 30, 2016 were $57 and $84, respectively.

ACCRUED EXPENSES AND OTHER ACCOUNTS PAYABLE

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND OTHER ACCOUNTS PAYABLE

NOTE 8:-

ACCRUED EXPENSES AND OTHER ACCOUNTS PAYABLE

	December 31,		June 30,
	2016		2016		2015

Accrued expenses	$	4,209	$	5,615	$	4,735
Government authorities		1,568		1,406		536
Provision for contractual inventory purchase obligations *		2,009		2,834		1,304
Other		862		870		412

	$	8,648	$	10,725	$	6,987

See also Note 14e.

WARRANTY OBLIGATIONS

12 Months Ended

Dec. 31, 2016

Product Warranties Disclosures [Abstract]

WARRANTY OBLIGATIONS

NOTE 9:-

WARRANTY OBLIGATIONS

Changes in the Company’s product warranty liability for the six months ended December 31, 2016 and the years ended on June 30, 2016 and 2015 were as follows:

	December 31,			June 30,
	2016			2016			2015

Balance, at beginning of year	$	51,192		$	31,879		$	18,181
Additions and adjustments to cost of revenues		13,749			28,848			19,407
Usage and current warranty expenses		(6,566	)		(9,535	)		(5,709	)

Balance, at end of year		58,375			51,192			31,879
Less current portion		(13,616	)		(14,114	)		(9,431	)

Long term portion	$	44,759		$	37,078		$	22,448

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK

12 Months Ended

Dec. 31, 2016

Debt Instruments [Abstract]

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK

NOTE 10:-

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK

On December 28, 2012 (the “Agreement Date”), the Company entered into a loan facility agreement (the “Loan Agreement”) with a lender (the “Lender”), pursuant to which the Lender agreed to loan the Company up to $10,000. On the Agreement Date, the Company received a total of $10,000, less a $100 loan transaction fee paid to the Lender (the “Loan”). The Loan is for a period of 42 months and bears annual interest of 11.90%, which is to be paid monthly.

The principal of the loan is to be paid in 33 monthly payments, beginning in September 2013, except for the last loan payment which was paid in advance on the Agreement Date. Repayment of the Loan and payment of all other amounts owed to the Lender is paid in Euro.

Borrowings pursuant to the Loan Agreement are secured by a first priority security interest in all existing and future assets of the Company.

In connection with the Loan Agreement, the Company granted the Lender 563,014 warrants to purchase Series D-1 convertible preferred stock at an exercise price of $2.309 (the “Warrants”). The Warrants were exercisable in whole or in part prior to earliest of (i) the tenth anniversary of the Agreement Date or (ii) 12 months after a qualified initial public offering or (iii) immediately prior to the consumption of a merger or sale of all or substantially all of the Company’s assets (“M&A Transaction”, and together with a qualified initial public offering, an “Exit Event”).

If (i) the Lender exercised all Warrants in full upon or after an Exit Event, and (ii) the intrinsic value of the Warrants upon such exercise is lower than $750, the Company should pay to the Lender, in addition to any other amounts due to the Lender under the Loan Agreement, an amount equal to the difference between $750 and the Warrants’ intrinsic value.

On the Agreement Date, the Company recorded its freestanding Warrants to purchase its convertible preferred stock in the amount of $778 as a liability at their fair value upon issuance, by utilizing an option pricing method. The fair value of the Warrants was subject to remeasurement at each balance sheet date with any change in value being reflected as financial expenses, net.

Upon exercise or expiration, the Warrants will be reclassified to stockholders’ equity (deficiency), at which time the Warrant liability will no longer be subject to fair value accounting.

The fair value of the Warrants liability on the Agreement Date in the amount of $778 represented a loan discount which was amortized to financial expenses over the period of the Loan by using the effective interest method. The residual amount of $9,122 (net of the $100 loan transaction fee) was allocated to the Loan.

Issuance expenses in the amount of $75 were allocated to the warrants to purchase convertible preferred stock liability and to the Loan, according to the above recorded values ratio. Issuance expenses in the amount of $6 related to the Warrants liability were immediately expensed and recorded as financial expenses, net. Issuance expenses in the amount of $69 related to the Loan were recorded as deferred charge assets (classified to short-term and long-term assets). The deferred charge assets were amortized over the period of the Loan by using the effective interest method.

Upon the closing of the IPO, all outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock (See Note 1c).

As of June 30, 2014, the Warrants liability has been measured at fair value in the amount of $765.

In January 2015, the Company fully settled the amount borrowed from the Lender under the Term Loan.

On June 18, 2015 the Lender elected to exercise its cashless exercise rights under which the Company issued 154,768 shares of common stock. The fair value of the Warrants liability as of the exercise date in the amount of $6,115 was reclassified to stockholders’ equity (deficiency).

REVOLVING CREDIT LINE

12 Months Ended

Dec. 31, 2016

Line of Credit Facility [Abstract]

REVOLVING CREDIT LINE

NOTE 11:-

REVOLVING CREDIT LINE

In June 2011, the Company entered into an agreement for a revolving line of credit from a Bank Lender (the "Bank Lender"), which, as amended to date, permits aggregate borrowings of up to $20,000 in an amount not to exceed 80% of the eligible trade receivables plus 65% of inventories in transit to customers and bears interest, payable monthly, at the Bank Lender’s prime rate plus a margin of 0.75% to 2.75%.

On February 17, 2015, the Company amended and restated the agreement with the Bank Lender for a revolving line of credit, which permits aggregate borrowings of up to $40,000 in an amount not to exceed 80% of the eligible accounts receivable and bears interest, payable monthly, at the Bank Lender’s prime rate plus a margin of 0.5% to 2.0%. As of December 31, 2016, the revolving line of credit was terminated and the Company had no outstanding borrowings related to this revolving line of credit.

As of June 30, 2016 and 2015, the Company met all its Bank Lender covenants.

As of June 30, 2016 and 2015, the Company had no outstanding borrowings related to this revolving line of credit.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

12 Months Ended

Dec. 31, 2016

Accumulated Other Comprehensive Income Loss

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

NOTE 12:- ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), net of taxes, for the six months ended December 31, 2016:

	Unrealized gains (losses) on available-for-sale marketable securities			Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total

Beginning balance	$	57		$	243		$	(29	)	$	271
Other comprehensive income (loss) before reclassifications		(193	)		93			(178	)		(278	)
Losses (gains) reclassified from accumulated other comprehensive income (loss)		-			(317	)		-			(317	)
Net current period other comprehensive income (loss)		(193	)		(224	)		(178	)		(595	)

Ending balance	$	(136	)	$	19		$	(207	)	$	(324	)

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the year ended June 30, 2016:

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total

Beginning balance	$	-	$	-		$	(222	)	$	(222	)
Other comprehensive income (loss) before reclassifications		56		412			193			661
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1		(169	)		-			(168	)
Net current period other comprehensive income (loss)		57		243			193			493

Ending balance	$	57	$	243		$	(29	)	$	271

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the year ended June 30, 2015:

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges		Unrealized gains (losses) on foreign currency translation			Total

Beginning balance	$	-	$	-	$	(61	)	$	(61	)
Other comprehensive income (loss) before reclassifications		-		-		(161	)		(161	)
Losses (gains) reclassified from accumulated other comprehensive income (loss)		-		-		-			-
Net current period other comprehensive income (loss)		-		-		(161	)		(161	)

Ending balance	$	-	$	-	$	(222	)	$	(222	)

The following tables provides details about reclassifications out of accumulated other comprehensive income (loss):

Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statements of Operations
	Six months ended
	December 31, 2016

Unrealized gains (losses) on cash flow hedges	$	47		Cost of revenues
		227		Research and development
		58		Sales and marketing
		46		General and administrative

		378		Total, before income taxes

		(61	)	Income tax expense (benefit)

	$	317		Total, net of income taxes

Unrealized gains (losses) on available-for-sale marketable securities	$	-		Financial income, net
		-		Income tax expense (benefit)

	$	-		Total, net of income taxes

	$	317		Total, net of income taxes

Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statements of Operations
	Year ended
	June 30, 2016

Unrealized gains (losses) on cash flow hedges	$	30		Cost of revenues
		115		Research and development
		33		Sales and marketing
		24		General and administrative

		202		Total, before income taxes

		(33	)	Income tax expense (benefit)

	$	169		Total, net of income taxes

Unrealized gains (losses) on available-for-sale marketable securities	$	(1	)	Financial income, net
		-		Income tax expense (benefit)

	$	(1	)	Total, net of income taxes

	$	168		Total, net of income taxes

No amounts were reclassified from accumulated other comprehensive income for the years ended June 30, 2015 and 2014.

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

DERIVATIVE INSTRUMENTS

12 Months Ended

Dec. 31, 2016

Derivative Instruments

DERIVATIVE INSTRUMENTS

NOTE 13:- DERIVATIVE INSTRUMENTS

The fair value of the Company’s outstanding derivative instruments is as follows:

	As of December 31,		As of June 30,
	2016		2016			2015

Derivative assets:
Derivatives not designated as cash flow hedging instruments:
Foreign exchange option contracts	$	-	$	214		$	-
Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts		19		290			-

Total	$	19	$	504		$	-

Derivative liabilities:
Derivatives not designated as cash flow hedging instruments:
Foreign exchange option contracts	$	-	$	(23	)	$	-

Total	$	-	$	(23	)	$	-

The Company recorded the fair value of derivative assets and liabilities, net in “prepaid expenses and other accounts receivable” on the Company’s consolidated balance sheets.

The increase (decrease) in unrealized gains (losses) recognized in “accumulated other comprehensive income (loss)” on derivatives, net of tax effect, is as follows:

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts	$	93	$	412	$	-	$	-

Total	$	93	$	412	$	-	$	-

The net (gains) losses reclassified from “accumulated other comprehensive income (loss)” into income (loss), are as follows:

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015		2014

Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts	$	(317	)	$	(169	)	$	-	$	-

Total	$	(317	)	$	(169	)	$	-	$	-

The Company recorded in the financial income (expenses), a net gain (loss) of $(87), $(136), $1,721 and $(189) during the six months ended Decmber 31, 2016 and years ended June 30, 2016 , 2015 and 2014, respectively related to derivatives not qualified as hedging instruments.

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

12 Months Ended

Dec. 31, 2016

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 14:-

COMMITMENTS AND CONTINGENT LIABILITIES

Lease commitments:

The Company and its subsidiaries lease their operating facilities under non-cancelable operating lease agreements, which expire over the next eight years, with the last ending in December 2024.

The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises, that are in effect as of December 31, 2016, are as follows:

2017	$	3,151
2018		2,561
2019		2,231
2020		1,698
2021		1,538
2022 and thereafter		4,466

	$	15,645

Rent expenses for the six months ended Decmber 31, 2016 and for the years ended June 30, 2016, 2015 and 2014, were approximately $1,199, $2,238, $1,714 and $1,200, respectively.

Guarantees:

As of December 31, 2016, contingent liabilities exist regarding guarantees in the amount of $617, $52 and $166 in respect of office rent lease agreements, customs transactions and credit card limits, respectively.

Royalty commitments:

On April 12, 2009, the Company received approval for a grant in a total amount of $703, from the BIRD-F in conjunction with a mutual development project with an American corporation.

Under the Company’s research and development agreements with the BIRD-F, and pursuant to applicable law, the Company is required to pay royalties at the rate of 5% of gross sales of products developed with funds provided by the BIRD-F, up to an amount equal to 150% of the research and development grants (dollar-linked) received from the BIRD-F. The obligation to pay these royalties is contingent on actual sales of the products and, in the absence of such sales, no payment is required. Royalties payable with respect to grants received from the BIRD-F are linked to the Consumer Price Index in the U.S.

At the end of 2011, the American corporation that had partnered with the Company announced the discontinuation of its solar business, resulting in the termination of the mutual development agreements. As a result, the development has not advanced into a commercial product. The Company does not expect any revenues from such project or the utilization of the technology mutually developed.

As of December 31, 2016, the aggregate contingent liability to the BIRD-F amounted to approximately $1,148 which would be payable by the Company if the project were to generate revenues.

Governmental commitments:

The Company has received royalty-bearing grants sponsored by the Israeli government for the support of research and development activities. Through June 30, 2015, the Company had obtained grants from the OCS for certain of the Company’s research and development projects. The Company is obligated to pay royalties to the OCS, amounting to 4% in the first three years, and 4.5% thereafter, of the sales of the products and other related revenues (based on the dollar equivalent amount of the grant) generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.

As of December 31, 2016, the aggregate contingent liability to the OCS with respect to royalty-bearing participation, net of royalties accrued, amounted to $1,022 out of which the Company already recorded a provision for royalties in the amount of $260. The total research and development grants that the Company has received from the OCS as of December 31, 2016 were $990. The accumulated interest as of December 31, 2016 was $32.

Royalty expenses relating to the OCS grants included in cost of revenues for the six months ended December 31, 2016, amounted to $260.

As of June 30, 2016 and 2015, there have been no sales or revenues on which royalties are payables.

The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the OCS. Such approval is not required for the sale or export of any products resulting from such research or development.

The OCS, under special circumstances, may approve the transfer of OCS-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the OCS a portion of the sale price paid in consideration for such OCS-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its OCS-funded know-how; (c) such transfer of OCS-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) if such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient.

Contractual purchase obligations:

The Company has contractual obligations to purchase goods and raw materials. These contractual purchase obligations relate to inventories held by contract manufacturers and purchase orders initiated by the contract manufacturers, which cannot be canceled without penalty. The Company utilizes third parties to manufacture its products.

In addition, it acquires raw materials or other goods and services, including product components, by issuing to suppliers authorizations to purchase based on its projected demand and manufacturing needs. As of December 31, 2016, the Company had non-cancelable purchase obligations totaling approximately $65,345 out of which the Company already recorded a provision for loss in the amount of $2,009 (see also Note 8).

Legal claims:

From time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. These accruals are reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular matter.

LEASE INCENTIVE OBLIGATION

12 Months Ended

Dec. 31, 2016

Leases [Abstract]

LEASE INCENTIVE OBLIGATION

OTE 15:-

LEASE INCENTIVE OBLIGATION

The Company has an operating lease agreement for building in Herzilia, Israel. In connection with this lease, the Company and its third party lessor (the "Lessor"), agreed that the Lessor would pay approximately $2,938 for certain leasehold improvements on behalf of the Company.

As of December 31, 2016, the Company received in cash the entire amount of $2,938 from the Lessor in connection with such leasehold improvements. These leasehold improvements are accounted for as a lease incentive obligation, which is recorded under long-term liabilities, net of the current portion recorded in accrued expenses and other accounts payable under current liabilities. The lease incentive obligation is being amortized over the life of the lease and as a reduction to rent expense. As of December 31, 2016, the net amortized amount of lease incentive obligation is $2,345, out of which $2,061 was recorded under long-term liabilities.

CONVERTIBLE PREFERRED STOCK

12 Months Ended

Dec. 31, 2016

Temporary Equity Disclosure [Abstract]

CONVERTIBLE PREFERRED STOCK

NOTE 16:-

CONVERTIBLE PREFERRED STOCK

Composition of convertible preferred stock of the Company:

	Authorized						Issued and outstanding
	Number of shares
	December 31,		June 30,				December 31,		June 30,
	2016		2016		2015		2016		2016		2015

Stock of $0.0001 par value:
Preferred stock		95,000,000		95,000,000		95,000,000		-		-		-

The Company issued Series A through E Preferred stock between the years 2006 and 2015. The Company classified the convertible preferred stock outside of stockholders’ equity (deficiency) as required by ASC 480-10-S99-3A and ASR 268, since the shares possessed deemed liquidation features that could trigger a distribution of cash or assets not solely within the Company’s control.

Prior to the consummation of the Company’s IPO on March 31, 2015, the Company had the following convertible preferred stock outstanding, all of which was converted into common stock following with the IPO on March 31, 2015 (see Note 1c) which resulted in classification of convertible preferred stock temporary equity in the amount of $140,915 into stockholders’ equity (deficiency):

	Shares outstanding		Number of shares of Common Stock issued upon conversion

Series A Preferred stock		15,558,830		5,186,276
Series B Preferred stock		18,760,196		6,253,398
Series C Preferred stock		15,984,655		5,328,217
Series D Preferred stock		16,024,251		5,341,416
Series D-1 Preferred stock		2,165,441		721,813
Series D-2 Preferred stock		2,598,528		866,175
Series D-3 Preferred stock		4,330,872		1,443,623
Series E Preferred stock		9,321,019		3,107,005
		84,743,792		28,247,923

STOCK CAPITAL

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK CAPITAL

NOTE 17:-

STOCK CAPITAL

Composition of common stock capital of the Company:

	Authorized						Issued and outstanding
	Number of shares
	December 31,		June 30,				December 31,		June 30,
	2016		2016		2015		2016		2016		2015

Stock of $0.0001 par value:
Common stock		125,000,000		125,000,000		125,000,000		41,259,391		40,889,922		39,297,539

Common stock rights:

Common stock confers upon its holders the right to receive notice of, and to participate in, all general meetings of the Company, where each share of common stock shall have one vote for all purposes; to share equally, on a per share basis, in bonuses, profits or distributions out of fund legally available therefor; and to participate in the distribution of the surplus assets of the Company in the event of liquidation of the Company.

On March 23, 2015, the Company's board of directors and the requisite holders of the Company's capital stock consented to a 1-for-3 reverse stock split of the Company's common stock.

As a result of the reverse stock split, (i) every 3 shares of authorized, issued and outstanding common stock was decreased to one share of authorized, issued and outstanding common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased on a 1-for-3 basis, (iii) all share prices and exercise prices were proportionately increased. All of the share numbers, share prices, and exercise prices have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 1-for-3 reverse stock split.

Stock option plans:

The Company’s 2007 Global Incentive Plan (the “2007 Plan”) was adopted by the board of directors on August 30, 2007. The 2007 Plan terminated upon the Company’s IPO on March 31, 2015 and no further awards may be granted thereunder. All outstanding awards will continue to be governed by their existing terms and 379,358 available options for future grant were transferred to the Company’s 2015 Global Incentive Plan (the “2015 Plan”) and are reserved for future issuances under the 2015 plan.

The 2015 Plan became effective upon the consummation of the IPO. The 2015 Plan provides for the grant of options, RSUs and other share-based awards to directors, employees, officers and consultants of the Company and its Subsidiaries. As of December 31, 2016, a total of 3,827,117 shares of common stock were reserved for issuance pursuant to stock awards under the 2015 Plan (the “Share Reserve”).

The Share Reserve will automatically increase on January 1st of each year during the term of the 2015 Plan commencing on January 1st of the year following the year in which the 2015 Plan becomes effective in an amount equal to 5% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year; provided, however, that the Company’s board of directors may determine that there will not be a January 1st increase in the Share Reserve in a given year or that the increase will be less than 5% of the shares of capital stock outstanding on the preceding December 31st.

The aggregate maximum number of shares of common stock that may be issued on the exercise of incentive stock options is 10,000,000. As of December 31, 2016, an aggregate of 1,522,068 options are still available for future grant under the 2015 Plan.

A summary of the activity in the share options granted to employees and members of the board of directors for the six months ended December 31, 2016 and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2016		4,837,364			4.50		6.58		74,292
Granted		197,821			16.79
Exercised		(133,666	)		2.54
Forfeited or expired		(37,050	)		4.94
Outstanding as of December 31, 2016		4,864,469			5.05		6.24		39,585

Vested and expected to vest as of December 31, 2016		4,741,728			4.97		6.21		38,853

Exercisable as of December 31, 2016		3,388,429			3.50		5.42		31,105

A summary of the activity in the share options granted to employees and members of the board of directors for the year ended June 30, 2016 and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2015		6,034,782		$	3.14		7.06	$	200,438
Granted		238,400			24.92
Exercised		(1,379,668	)		2.07
Forfeited or expired		(56,150	)		4.03
Outstanding as of June 30, 2016		4,837,364		$	4.50		6.58	$	74,292

Vested and expected to vest as of June 30, 2016		4,673,944		$	4.42		6.54	$	72,114

Exercisable as of June 30, 2016		3,146,546		$	3.10		5.63	$	52,141

A summary of the activity in the share options granted to employees and members of the board of directors for the year ended June 30, 2015 and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2014		4,007,116		$	2.13		6.82	$	6,384
Granted		2,116,123		$	5.05
Exercised		(31,981	)	$	2.36
Forfeited or expired		(56,476	)	$	3.42
Outstanding as of June 30, 2015		6,034,782		$	3.14		7.06	$	200,438

Vested and expected to vest as of June 30, 2015		5,742,327		$	3.08		6.97	$	191,067

Exercisable as of June 30, 2015		3,551,239		$	2.17		5.71	$	121,373

The aggregate intrinsic value in the tables above represents the total intrinsic value (the difference between the fair value of the Company’s common stock as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period.

The total intrinsic value of options exercised during the six months ended December 31, 2016 and the years ended June 30, 2016 and 2015 was $1,790, $30,670 and $484, respectively.

The weighted average grant date fair values of options granted to employees and executive directors during the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014 were $8.86, $13.27, $4.24 and $1.98, respectively.

The options outstanding as of December 31, 2016, have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	December 31,		contractual		December 31,		contractual
price	2016		Life in years		2016		Life in years
$0.87 - $1.50		677,625		2.14		677,625		2.14
$1.68 - $2.46		1,340,663		4.71		1,338,271		4.71
$3.03 - $3.96		482,216		7.03		330,770		7.00
$5.01		1,901,081		7.90		945,130		7.90
$9.36		26,663		8.08		12,775		8.08
$15.34		39,000		9.73		2,436		9.73
$17.14		158,821		9.65		9,922		9.65
$20.81		9,600		9.40		-		-
$25.09		228,800		8.64		71,500		8.64

		4,864,469		6.24		3,388,429		5.42

The options outstanding as of June 30, 2016, have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	June 30,		contractual		June 30,		contractual
price	2016		Life in years		2016		Life in years
$0.87 - $1.50		707,091		2.65		707,091		2.65
$1.68 - $2.46		1,411,951		5.22		1,381,725		5.20
$3.03 - $3.96		514,489		7.55		287,763		7.52
$5.01		1,933,216		8.42		715,300		8.41
$9.36		32,217		8.44		11,767		8.19
$20.81		9,600		9.91		-		-
$25.09		228,800		9.14		42,900		9.14

		4,837,364		6.58		3,146,546		5.63

The options outstanding as of June 30, 2015, have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	June 30,		contractual		June 30,		contractual
price	2015		Life in years		2015		Life in years

$0.87		490,165		3.14		490,165		3.14
$1.50 - $1.68		771,321		4.04		771,321		4.04
$2.01 - $2.46		2,075,550		6.30		1,794,228		6.24
$3.03 - $3.96		668,270		8.54		247,767		8.46
$5.01		1,996,148		9.42		247,758		9.40
$9.36		33,328		9.59		-		-

		6,034,782		7.08		3,551,239		5.71

A summary of the activity in the RSUs granted to employees and members of the board of directors for the six months ended December 31, 2016, is as follows:

	No. of RSUs			Weighted average grant date fair value
Unvested as of July 1, 2016		834,186			24.74
Granted		874,032			15.74
Vested		(143,303	)		22.01
Forfeited		(49,897	)		24.11
Unvested as of December 31, 2016		1,515,018			19.74

A summary of the activity in the RSUs granted to employees and members of the board of directors for the year ended June 30, 2016, is as follows:

	No. of RSUs			Weighted average grant date fair value
Unvested as of July 1, 2015		67,440			25.09
Granted		981,321			24.77
Vested		(161,173	)		24.36
Forfeited		(53,402	)		18.46
Unvested as of June 30, 2016		834,186			24.74

A summary of the activity in the RSUs granted to employees and members of the board of directors for the year ended June 30, 2015, is as follows:

	No. of RSUs		Weighted average grant date fair value
Unvested as of July 1, 2014		-		-
Granted		67,440		25.09
Vested		-		-
Forfeited		-		-
Unvested as of June 30, 2015		67,440		25.09

Options and RSUs issued to non-employee consultants:

The Company has granted options to purchase common shares and RSU’s to non-employee consultants as of December 31, 2016 as follows:

	Options & RSU’s
	outstanding				Exercisable
	as of				as of
Issuance	December 31,		Exercise		December 31,		Exercisable
Date	2016		price		2016		Through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		5,166	October 24, 2022
January 23, 2013		3,333		3.03		3,333	January 23, 2023
January 27, 2014		4,148		3.51		2,552	January 27, 2024
May 1, 2014		3,250		3.51		1,542	May 1, 2024
September 17, 2014		10,830		3.96		6,823	September 17, 2024
October 29, 2014		5,638		5.01		1,860	October 29, 2024
August 19, 2015		17,699		0.00		-
November 8, 2015		2,491		0.00		-
April 18, 2016		2,084		0.00		-
July 11, 2016		2,667		0.00		-
September 21, 2016		4,000		15.34		250	September 21, 2026
September 21, 2016		6,563		0.00		-

		101,202				54,859

The Company has granted options to purchase common shares and RSU’s to non-employee consultants as of June 30, 2016 as follows:

	Options & RSU’s
	outstanding				Exercisable
	as of				as of
Issuance	June 30,		Exercise		June 30,		Exercisable
Date	2016		price		2016		Through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		4,749	October 24, 2022
January 23, 2013		3,333		3.03		2,986	January 23, 2023
January 27, 2014		4,248		3.51		2,069	January 27, 2024
May 1, 2014		6,000		3.51		3,542	May 1, 2024
September 17, 2014		10,830		3.96		5,466	September 17, 2024
October 29, 2014		5,638		5.01		1,192	October 29, 2024
August 19, 2015		21,501		0.00		-
November 8, 2015		4,167		0.00		-
April 18, 2016		2,500		0.00		-

		96,716				53,337

The Company has granted options to purchase common shares to non-employee consultants as of June 30, 2015 as follows:

	Options
	outstanding				Exercisable
	as of				as of
Issuance	June 30,		Exercise		June 30,		Exercisable
Date	2015		price		2015		Through

July 31, 2008		33,333	$	0.87		33,333	July 31, 2018
January 26, 2011		5,000	$	2.01		5,000	January 26, 2021
January 26, 2012		33,333	$	2.46		33,333	January 26, 2022
October 24, 2012		6,666	$	2.46		4,583	October 24, 2022
January 23, 2013		3,333	$	3.03		2,153	January 23, 2023
January 27, 2014		4,998	$	3.51		1,652	January 27, 2024
May 1, 2014		6,000	$	3.51		2,042	May 1, 2024
September 17, 2014		19,163	$	3.96		3,662	September 17, 2024
October 29, 2014		6,668	$	5.01		890	October 29, 2024

		118,494				86,648

The Company accounts for its options granted to non-employee consultants under the fair value method of ASC 505-50 (“Equity-Based Payments to Non-Employees”).

In connection with the grant of stock options to non-employee consultants, the Company recorded stock compensation expenses in the six months ended December 31, 2016 and the years ended June 30, 2016, 2015 and 2014 in the amounts of $66, $524, $563 and $55, respectively.

Employee Stock Purchase Plan (“ESPP”):

The Company adopted an Employee Stock Purchase Plan (the “ESPP”) effective upon the consummation of the IPO. As of December 31, 2016, a total of 888,569 shares were reserved for issuance under this plan. The number of shares of common stock reserved for issuance under the ESPP will increase automatically on January 1st of each year, for ten years, by the lesser of 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or 487,643 shares.

However, the Company’s board of directors may reduce the amount of the increase in any particular year at their discretion, including a reduction to zero.

The ESPP is implemented through an offering every six months. According to the ESPP, eligible employees may use up to 10% of their salaries to purchase common stock shares up to an aggregate limit of $10 per participant for every six months plan. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the subscription date of each offering period or on the purchase date.

As of December 31, 2016, 83,319 common stock shares had been purchased under the ESPP.

As of December 31, 2016, 805,250 common stock shares were available for future issuance under the ESPP.

In accordance with ASC No. 718, the ESPP is compensatory and as such results in recognition of compensation cost.

Stock-based compensation expense for employees and non-employee consultants:

The Company recognized stock-based compensation expenses related to stock options and RSUs granted to employees and non-employee consultants and ESPP in the consolidated statement of operations for the six months ended December 31, 2016 and for the years ended June 30, 2016, 2015 and 2014, as follows:

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Cost of revenues	$	871	$	945	$	442	$	108
Research and development, net		2,061		2,364		635		397
Selling and marketing		1,852		2,915		809		297
General and administrative		1,816		2,820		1,070		280

Total stock-based compensation expense	$	6,600	$	9,044	$	2,956	$	1,082

As of December 31, 2016, there was a total unrecognized compensation expense of $36,461 related to non-vested equity-based compensation arrangements granted under the Company’s Plans. These expenses are expected to be recognized during the period from January 1, 2017 through November 30, 2020.

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

Nonoperating Income (Expense) [Abstract]

INCOME TAXES

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 18:- INCOME TAXES

Tax rates in U.S. and Germany:

The Company is subject to U.S. federal tax at the rate of 34%, and the Company’s German subsidiary is subject to German tax at the rate of 33%.

Corporate tax in Israel:

Taxable income of Israeli companies is subject to corporate tax at the rate of 26.5% in the year ended June 30, 2014 and 2015, and 25% in the year ended June 30, 2016 onwards (see also Note 18i).

In January 2016, the Law for Amending the Income Tax Ordinance (No. 216) (Reductio of Corporate Tax Rate), 2016 was approved, which includes a reduction of the corporate tax rate from 26.5% to 25%, effective from January 1, 2016.

In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018.

Carryforward tax losses:

As of December 31, 2016, the Company has no federal or state carryforward tax losses.

As of December 31, 2016, the Israeli subsidiary has no Israeli net carryforward tax losses.

Deferred income taxes:

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

The Company’s Israeli subsidiary’s tax-exempt profit from Approved Enterprises and Benefited Enterprises is permanently reinvested as the Company’s management has determined that the Company does not currently intend to distribute dividends. Therefore, deferred taxes have not been provided for such tax-exempt income. The Company intends to continue to reinvest these profits and does not currently foresee a need to distribute dividends out of such tax-exempt income."

The Company does not have a provision for U.S. Federal income taxes on the undistributed earnings of its international subsidiaries because such earnings are considered to be indefinitely reinvested.

Uncertain tax positions:

The Company recognaized for the first time a total liability for uncertain tax positions in the amount of $0.3 million as of December 31, 2016.

Significant components of the Company’s deferred tax liabilities and assets are as follows:

	December 31,		June 30,
	2016		2016		2015

Assets in respect of:

Carryforward tax losses	$	-	$	4,186	$	23,033
Research and Development carryforward expenses- temporary differences		908		743		5,173
Other reserves		1,907		1,367		1,346

		2,815		6,296		29,552

Valuation allowance (1)		-		-		(29,552	)

Deferred tax assets, net	$	2,815	$	6,296	$	-

(1) ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluated the net deferred tax assets for each separate tax entity. As of June 30, 2015, the Company concluded that it is not more likely than not that the net deferred tax assets will be realized and a full valuation allowance has been recorded against these assets. The Company's estimate of future book-taxable income considers available evidence, both positive and negative, about its operating businesses and investments, including an aggregation of individual projections for each significant operating business and investment, estimated apportionment factors for state and local taxing jurisdictions and includes all future years that the Company estimated it would have available net operating loss carryforwards.

During fiscal year 2016, the Company determined that the positive evidence outweighs the negative evidence for deferred tax assets and concluded that these deferred tax assets are realizable on a "more likely than not" basis. This determination was mainly due to expected future results of positive operations and earnings history.

Income before taxes is comprised as follows:

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015

Domestic	$	3,165	$	3,758	$	2,830
Foreign		27,433		68,472		20,246

	$	30,598	$	72,230	$	23,076

Taxes on income (tax benefit) are comprised as follows:

	Six months ended December 31,		Year ended June 30,
	2016		2016			2015		2014
Domestic taxes:
Current		1,047		1,737			1,655		100
Deferred		507		(1,380	)		-		-
Foreign taxes:
Current		518		263			300		120
Deferred		3,145		(4,999	)		-		-

	$	5,217	$	(4,379	)	$	1,955	$	220

Reconciliation of theoretical tax expense to actual tax expense:

The differences between the statutory tax rate of the Company and the effective tax rate are primarily accounted for by the non-recognition of tax benefits from accumulated net carryforward tax losses among the Company and various subsidiaries due to uncertainty of the realization of such tax benefits.

A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows:

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015			2014

Income (loss) before taxes, as reported in the consolidated statements of operations	$	30,598		$	72,230		$	23,076		$	(21,158	)

Statutory tax rate		34	%		34	%		35	%		35	%
Theoretical tax benefits on the above amount at the US statutory tax rate		10,403			24,558			8,077			(7,405	)
Income tax at rate other than the U.S. statutory tax rate		(5,396	)		(30,229	)		(9,305	)		9,172
Impact of Israel corporate tax rate change		-			-			-			(2,103	)
Non-deductible expenses		164			1,514			3,003			467
Other individually immaterial income tax items		46			(222	)		180			89

Actual tax expense (tax benefit)	$	5,217		$	(4,379	)	$	1,955		$	220

Tax assessments:

As of December 31, 2016, the Company and certain of its subsidiaries filed U.S. federal and various state and foreign income tax returns. The statute of limitations relating to the consolidated U.S. federal income tax return is closed for all tax years up to and including 2013.

The statute of limitations related to tax returns of the Company’s Israeli subsidiary is closed for all tax years up to and including 2011.

The statute of limitations related to tax returns of the Company’s German subsidiary is closed for all tax years up to and including 2011.

With respect to the Company’s, Chinese, Australian, Canadian, Dutch, Japanese, UK, French, Italian, Bulgarian and Turkish subsidiaries, the statute of limitations related to its tax returns is open for all tax years since incorporation.

The Company believes that it has adequately provided for reasonably foreseeable outcomes related to tax audits and settlements. The final tax outcome of any Company tax audits could be different from that which is reflected in the Company’s income tax provisions and accruals. Such differences could have a material effect on the Company’s income tax provision and net income (loss) in the period in which such determination is made.

Tax benefits for Israeli companies under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):

The Israeli subsidiary elected tax year 2012 as a "Year of Election" for “Beneficiary Enterprise” status under the Investment Law, which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular corporate tax rate. Upon meeting the requirements under the Investment Law, income derived from Beneficiary Enterprise from productive activity will be exempt from tax for two years from the year in which the Israeli subsidiary first has taxable income, provided that 12 years have not passed from the beginning of the year of election. In the six months ended December 31, 2016 Israeli subsidiary utilized all of her operating loss carryforwards in Israel and became profitable for tax purposes. As of December 31, 2016, Israeli subsidiary is entitled to benefit from a two year tax exemption as part of the Beneficiary Enterprise .

If dividends are distributed out of tax exempt profits, the Israeli subsidiary will then become liable for tax at the rate applicable to its profits from the Beneficiary Enterprise in the year in which the income was earned, as if it had not chosen the alternative track of benefits.

The dividend recipient is subject to withholding tax at the rate of 15% applicable to dividends from Beneficiary enterprises, if the dividend is distributed during the tax benefits period or within twelve years thereafter. This limitation does not apply to a foreign investors' company. The Israeli subsidiary currently has no plans to distribute dividends and intends to retain future earnings to finance the development of its business.

Through December 31, 2016, the Israeli subsidiary had generated income under the provision of the Investment Law.

As of December 31, 2016, approximately $26,459 was derived from tax exempt profits earned by the Israeli subsidiary “Beneficiary Enterprises.” The Company has determined that such tax-exempt income will not be distributed as dividends and intends to reinvest the amount of its tax exempt income earned by the Israeli subsidiary. Accordingly, no provision for deferred income taxes has been provided on income attributable to the Israeli subsidiary “Beneficiary Enterprises” as such income is essentially permanently reinvested.

If the Israeli subsidiary retained tax-exempt income is distributed, the income would be taxed at the applicable corporate tax rate which depend on the foreign ownership in each tax year, the tax rate can range between 10% (when foreign ownership exceeds 90%) to 20% (when foreign ownership exceeds 49%). There can be no assurance that the Israeli subsidiary will continue to qualify as an foreign investor company in the future or that the benefits described herein will be granted in the future.

Amendment to the Law for the Encouragement of Capital Investments, 1959 (Amendment 71):

On August 5, 2013, the Israeli Parliament issued the Law for Changing National Priorities (Legislative Amendments for Achieving Budget Targets for 2013 and 2014), 2013 which consists of Amendment 71 to the Law for the Encouragement of Capital Investments ("the Amendment"). According to the Amendment, the tax rate on preferred income form a preferred enterprise in 2014 and thereafter will be 16% (in development area A - 9%).

The Amendment also prescribes that any dividends distributed to individuals or foreign residents from the preferred enterprise's earnings as above will be subject to tax at a rate of 20%.

Amendment to the Law for the Encouragement of Capital Investments, 1959 (Amendment 73):

In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law for the Encouragement of Capital Investments ("the Amendment") was published. According to the Amendment, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2017 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).

The Amendment also prescribes special tax tracks for technological enterprises, which are subject to rules that are to be issued by the Minister of Finance by March 31, 2017.

The new tax tracks under the Amendment are as follows:

Technological preferred enterprise - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion. A technological preferred enterprise, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).

Special technological preferred enterprise - an enterprise for which total consolidated revenues of its parent company and all subsidiaries exceed NIS 10 billion. Such enterprise will be subject to tax at a rate of 6% on profits deriving from intellectual property, regardless of the enterprise's geographical location.

Any dividends distributed to "foreign companies", as defined in the Law, deriving from income from the technological enterprises will be subject to tax at a rate of 4%.

Since as of December 31, 2016 definitive criteria to determine the tax benefits had not yet been established, it cannot be concluded that the legislation in respect of technological enterprises had been enacted or substantively enacted as of that date. Accordingly, the above changes in the tax rates relating to technological enterprises were not taken into account in the computation of deferred taxes as of December 31, 2016.

The Law for Encouragement of Industry (Taxation), 1969:

The Israeli entity has the status of an "industrial company", as defined by this law. According to this status and by virtue of regulations published thereunder, The Israeli entity is entitled to claim a deduction of accelerated depreciation on equipment used in industrial activities, as determined in the regulations issued under the Inflationary Law. The Israeli entity is also entitled to amortize a patent or rights to use a patent or intellectual property that are used in the enterprise's development or advancement, to deduct issuance expenses for shares listed for trading, and to file consolidated financial statements under certain conditions.

Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.

There can be no assurance that the Company will continue to qualify as an Industrial Company or that the benefits described above will be available in the future.

FINANCIAL EXPENSES (INCOME), NET

12 Months Ended

Dec. 31, 2016

FINANCIAL EXPENSES (INCOME), NET

NOTE 19:-

FINANCIAL EXPENSES (INCOME), NET

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015			2014

Remeasurement of warrants to purchase convertible preferred stock	$	-		$	-		$	5,350		$	(53	)
Interest on term loan		-			-			579			1,475
Other financial expenses related to term loan		-			-			373			31
Expenses (income) related to hedging transaction		87			136			(1,721	)		189
Interest on short- term loan		-			-			316			537
Interest on marketable securities		(1,504	)		(1,112	)		-			-
Amortization of marketable securities premium and accretion of discount, net		685			532			-			-
Exchange rate loss (income), net, bank charges and other finance expenses		3,521			(27	)		180			608

	$	2,789		$	(471	)	$	5,077		$	2,787

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

NOTE 20:-

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

Summary information about geographic areas:

ASC 280 (“Segment Reporting”) establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling its products (see Note 1a for a brief description of the Company’s business).

The following is a summary of revenues within geographic areas:

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Revenues based on Customers’ location:
United States	$	160,321	$	334,260	$	238,340	$	64,607
Germany		11,076		22,207		13,290		15,133
Europe (*)		49,523		89,000		52,163		38,655
Rest of the World		19,077		44,376		21,285		14,822
Total revenues	$	239,997	$	489,843	$	325,078	$	133,217

(*) Except for Germany

Major Customers data as a percentage of total revenues:

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015			2014

Customer A		11.2	%		11.6	%		4.9	%		1.8	%
Customer B		8.7	%		10.9	%		24.6	%		19.1	%
Customer C		8.4	%		10.1	%		5.4	%		3.1	%

The following is a summary of revenues by product family :

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Inverters	$	112,585	$	223,756	$	156,984	$	62,085
Optimizers		115,229		244,852		158,513		65,018
Others		12,183		21,235		9,581		6,114
Total revenues	$	239,997	$	489,843	$	325,078	$	133,217

Long-lived assets by geographic region:

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015

Israel	$	35,055	$	26,751	$	14,136
U.S.		515		518		342
Europe		466		508		230
Other		86		54		9

Total long-lived assets*	$	36,122	$	27,831	$	14,717

Long-lived assets are comprised of property and equipment, net (marketable securities, prepaid expenses and lease deposits, intangible assets and deferred tax assets are not included).

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

TRANSITION PERIOD COMPARATIVE DATA

TRANSITION PERIOD COMPARATIVE DATA

12 Months Ended

Dec. 31, 2016

Transition Period Comparative Data

NOTE 21:- TRANSITION PERIOD COMPARATIVE DATA

The following table presents certain financial information (U.S. dollars in thousands except share and per share data):

	Six months ended December 31,
	2016		2015
			(Unaudited)

Revenues	$	239,997	$	239,886
Cost of revenues		159,097		167,777

Gross profit		80,900		72,109

Operating expenses:

Research and development, net		20,279		15,290
Sales and marketing		20,444		17,077
General and administrative		6,790		5,606

Total operating expenses		47,513		37,973

Operating income		33,387		34,136

Financial expenses, net		2,789		1,031

Income before taxes on income		30,598		33,105

Taxes on income (tax benefit)		5,217		(5,432	)

Net income	$	25,381	$	38,537

Net basic earnings per share of common stock	$	0.62	$	0.98

Net diluted earnings per share of common stock	$	0.58	$	0.87

Weighted average number of shares used in computing net basic earnings per share of common stock		41,026,926		39,406,797

Weighted average number of shares used in computing net diluted earnings per share of common stock		43,839,342		44,231,660

The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.

Principles of consolidation

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Principles of consolidation:

Use of estimates

Use of estimates:

Financial statements in U.S. dollars

Financial statements in U.S. dollars:

The resulting translation adjustments are reported as a component of stockholders’ equity (deficiency) in accumulated other comprehensive income (loss).

Accumulated other comprehensive loss related to foreign currency translation adjustments, net amounted to $207, $29 and $222 as of December 31, 2016, June 30, 2016 and 2015, respectively.

Basic and Diluted Net Earnings (Loss) Per Share

Basic and Diluted Net Earnings (Loss) Per Share:

Basic net earnings (loss) per share is computed by dividing the net earnings (loss) by the weighted-average number of shares of common stock outstanding during the period.

The following table presents the computation of basic and diluted net earnings (loss) per share for the periods presented (in thousands, except share and per share data):

	Six months Ended December 31,		Year ended June 30,
	2016		2016		2015			2014
Net basic earnings (loss) per share of common stock:
Numerator:
Net income (loss)		25,381		76,609		21,121			(21,378	)
Dividends accumulated for the period		-		-		(17,550	)		-
Net income (loss) available to shareholders of common stock		25,381		76,609		3,571			(21,378	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic		41,026,926		39,987,935		11,902,911			2,798,894

Net diluted earnings (loss) per share of common stock:
Numerator:
Net income (loss)		25,381		76,609		21,121			(21,378	)
Dividends accumulated for the period		-		-		(16,971	)		-
Net income (loss) available to shareholders of common stock		25,381		76,609		4,150			(21,378	)

Denominator:
Shares used in computing net earnings per share of common stock, basic		41,026,926		39,987,935		11,902,911			2,798,894
Effect of stock-based awards		2,812,416		4,388,140		3,366,537			-
Shares used in computing net earnings (loss) per share of common stock, diluted		43,839,342		44,376,075		15,269,448			2,798,894

Cash and cash equivalents

Cash and cash equivalents:

Cash equivalents are short-term, highly liquid investments that are readily convertible to cash, with original maturities of three months or less at the date acquired.

Marketable Securities

Marketable Securities:

Restricted cash

Restricted cash:

Inventories

Inventories:

Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.

Property, equipment and intangible assets

Property, equipment and intangible assets:

Property and equipment:

		%

Computers and peripheral equipment		20 – 33 (mainly 33)
Office furniture and equipment		7 – 15 (mainly 7)
Machinery & equipment		7 – 33 (mainly 20)
Laboratory equipment		15
Vehicles		15
Leasehold improvements		over the shorter of the lease term or useful economic life

Intangible assets:

Intangible assets are stated at cost, net of accumulated amortization. Amortization is calculated by the straight-line method over the estimated useful lives of the assets (see Note 7).

Impairment of long-lived assets

Impairment of long-lived assets:

Severance pay

k. Severance pay:

For the six months ended December 31, 2016, and the years ended June 30, 2016, 2015 and 2014, the Company recorded $1,131, $1,761, $1,273 and $1,109, severance expenses, respectively.

Revenue recognition

Revenue recognition:

Provisions for rebates, sales incentives, and discounts to customers are accounted for as reductions in revenue in the same period the related sales are recorded.

Revenues related to cloud-based monitoring and other services are recognized ratably on a straight-line basis over the estimated service period.

The Company’s process for determining its ESP considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable.

Cost of revenues

Cost of revenues:

Shipping and handling costs

Shipping and handling costs:

Warranty obligations

Warranty obligations:

The Company performs accelerated life cycle testing, which simulates the service life of the product in a short period of time.

Warranty obligations are classified as short-term and long-term warranty obligations based on the period in which the warranty is expected to be claimed.

Royalty-bearing grants from the Binational Industrial Research and Development Foundation

Royalty-bearing grants from the Binational Industrial Research and Development Foundation:

No grants were recorded in the six months ended December 31, 2016 and in the years ended June 30, 2016, 2015 and 2014.

Government grants

Government grants:

The Company recorded grants in the amount of $763 and $275 for the year ended June 30, 2015 and 2014, respectively, which was deducted from research and development expenses.

No grants were recorded for the six months ended December 31, 2016 and for the year ended June 30, 2016.

Research and development costs

Research and development costs:

Research and development costs, net of grants received, are charged to the consolidated statement of operations as incurred.

Concentrations of credit risks

Concentrations of credit risks:

The Company’s marketable securities consist of corporate and governmental bonds.

The trade receivables of the Company are derived from sales to Customers located primarily in North America, Europe and Australia.

The Company generally does not require collateral however, in certain circumstances, the Company may require letters of credit, other collateral or additional guarantees.

In addition, an accrual for rebates is allocated to specific debts. The Company accrued $9,089, $4,294 and $659 for rebates as of December 31, 2016, June 30, 2016 and 2015, respectively.

The Company and its subsidiaries have no off-balance sheet concentration of credit risk except for certain derivative instruments as mentioned below.

Fair value of financial instruments

t. Fair value of financial instruments:

The following methods and assumptions were used by the Company in estimating the fair value of its financial instruments:

Assets measured at fair value on a recurring basis as of December 31, 2016 and June 30, 2016 are comprised of foreign currency derivative contracts and marketable securities. (see Note 4)

Assets measured at fair value on a recurring basis as of June 30, 2015 are comprised of foreign currency forward contracts.

The Company applies ASC 820 (“Fair Value Measurements and Disclosures”), with respect to fair value measurements of all financial assets and liabilities.

A three-tiered fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

Level 1-

Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2-

Include other inputs that are directly or indirectly observable in the marketplace.

Level 3-

Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Warrants to Purchase Convertible Preferred Stock

Warrants to Purchase Convertible Preferred Stock:

The dividend yield assumption was zero as there is no history of dividend payments and the Company does not expect to pay any dividends in the foreseeable future.

The following assumptions were used to estimate the value of the warrants to purchase convertible preferred stock:

		June 30,
		2014

Expected volatility		45.0%
Risk-free rate		0.09%
Dividend yield		0%
Expected term (in years)		1.21

The change in the fair value of warrants to purchase convertible preferred stock is summarized below:

	Balance at beginning of period		Issuance of warrants to purchase preferred stock		Exercise of warrants to purchase common stock (*)			Change in fair value			Balance at end of period

June 30, 2015	$	765	$	-	$	(6,115	)	$	5,350		$	-
June 30, 2014	$	818	$	-	$	-		$	(53	)	$	765

(*)

Upon the closing of the IPO, all outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock (See Note 1c).

Accounting for stock-based compensation

Accounting for stock-based compensation:

Before the per share value was determined, a discount for lack of marketability and a voting right differential was applied, as applicable, to the common stock.

	Six months ended December 31,	Year ended June 30,
	2016	2016	2015	2014
Employee Stock Options
Risk-free interest	1.28% - 1.34%	1.39% - 1.97%	1.39% - 2.06%	1.62% - 1.94%
Dividend yields	0%	0%	0%	0%
Volatility	55.33% - 55.34%	55.45%-56.03%	46.5%-55.1%	46.3%-55.8%
Expected option term in years	6.06	5.50-6.11	5.50-6.27	6.02-6.27
Estimated forfeiture rate	0%	10.3%	12.5%-18.7%	14.0%

Employee Stock Purchase Plan
Risk-free interest	0.60%	0.40%	-	-
Dividend yields	0%	0%	-	-
Volatility	48.08%	62.84%	-	-
Expected term	6 months	6 months	-	-

	Six Months ended December 31,	Year ended June 30,
	2016	2016	2015	2014

Risk-free interest	1.16% - 2.45%	1.15%-2.21%	1.59%-2.58%	2.26%-2.75%
Dividend yields	0%	0%	0%	0%
Volatility	55.33% - 58.57%	55.37%-55.75%	45.5%-56.2%	45.0%-55.8%
Contractual life in years	6 - 10	6.4-10	7.4-10	8.3 - 10

Income taxes

Income taxes:

The Company and its subsidiaries provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

The company record reserves for uncertain tax positions to the extent it is more likely than not that the tax position will be sustained on audit, based on the technical merits of the position.

Derivative financial instruments

Derivative financial instruments:

As of December 31, 2016, the Company had no derivative instruments that are not designated as cash flows hedges.

The fair value of derivative assets as of December 31, 2016 was $19, which was recorded in other accounts receivable and prepaid expenses in the consolidated balance sheets (see Note 13).

Comprehensive income (loss)

Comprehensive income (loss):

Impact of recently issued accounting standards

The impact of recently issued accounting standards still not effective for the Company as of December 31, 2016 is as follows:

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of assumptions used to estimate fair value of stock options and warrants

		June 30,
		2014

Expected volatility		45.0%
Risk-free rate		0.09%
Dividend yield		0%
Expected term (in years)		1.21

Schedule of computation of basic and diluted net earnings (loss) per share

	Six months Ended December 31,		Year ended June 30,
	2016		2016		2015			2014
Net basic earnings (loss) per share of common stock:
Numerator:
Net income (loss)		25,381		76,609		21,121			(21,378	)
Dividends accumulated for the period		-		-		(17,550	)		-
Net income (loss) available to shareholders of common stock		25,381		76,609		3,571			(21,378	)

Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic		41,026,926		39,987,935		11,902,911			2,798,894

Net diluted earnings (loss) per share of common stock:
Numerator:
Net income (loss)		25,381		76,609		21,121			(21,378	)
Dividends accumulated for the period		-		-		(16,971	)		-
Net income (loss) available to shareholders of common stock		25,381		76,609		4,150			(21,378	)

Denominator:
Shares used in computing net earnings per share of common stock, basic		41,026,926		39,987,935		11,902,911			2,798,894
Effect of stock-based awards		2,812,416		4,388,140		3,366,537			-
Shares used in computing net earnings (loss) per share of common stock, diluted		43,839,342		44,376,075		15,269,448			2,798,894

Schedule of estimated useful lives of property and equipment

		%

Computers and peripheral equipment		20 – 33 (mainly 33)
Office furniture and equipment		7 – 15 (mainly 7)
Machinery & equipment		7 – 33 (mainly 20)
Laboratory equipment		15
Vehicles		15
Leasehold improvements		over the shorter of the lease term or useful economic life

Summary of change in fair value of warrants to purchase convertible preferred stock

	Balance at beginning of period		Issuance of warrants to purchase preferred stock		Exercise of warrants to purchase common stock (*)			Change in fair value			Balance at end of period

June 30, 2015	$	765	$	-	$	(6,115	)	$	5,350		$	-
June 30, 2014	$	818	$	-	$	-		$	(53	)	$	765

(*)

Upon the closing of the IPO, all outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock (See Note 1c).

Employee Stock Option [Member] | Employees and Members of Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of assumptions used to estimate fair value of stock options and warrants

	Six months ended December 31,	Year ended June 30,
	2016	2016	2015	2014
Employee Stock Options
Risk-free interest	1.28% - 1.34%	1.39% - 1.97%	1.39% - 2.06%	1.62% - 1.94%
Dividend yields	0%	0%	0%	0%
Volatility	55.33% - 55.34%	55.45%-56.03%	46.5%-55.1%	46.3%-55.8%
Expected option term in years	6.06	5.50-6.11	5.50-6.27	6.02-6.27
Estimated forfeiture rate	0%	10.3%	12.5%-18.7%	14.0%

Employee Stock Purchase Plan
Risk-free interest	0.60%	0.40%	-	-
Dividend yields	0%	0%	-	-
Volatility	48.08%	62.84%	-	-
Expected term	6 months	6 months	-	-

Employee Stock Option [Member] | Nonemployee Consultants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of assumptions used to estimate fair value of stock options and warrants

	Six Months ended December 31,	Year ended June 30,
	2016	2016	2015	2014

Risk-free interest	1.16% - 2.45%	1.15%-2.21%	1.59%-2.58%	2.26%-2.75%
Dividend yields	0%	0%	0%	0%
Volatility	55.33% - 58.57%	55.37%-55.75%	45.5%-56.2%	45.0%-55.8%
Contractual life in years	6 - 10	6.4-10	7.4-10	8.3 - 10

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

Schedule of Available-For-Sale Marketable Securities

MARKETABLE SECURITIES (Tables)

12 Months Ended

Dec. 31, 2016

Marketable Securities Tables

The following is a summary of available-for-sale marketable securities at December 31, 2016:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Corporate bonds	$	111,188	$	23	$	(213	)	$	110,998
Governmental bonds	$	7,762		-	$	(33	)	$	7,729

	$	118,950	$	23	$	(246	)	$	118,727

The following is a summary of available-for-sale marketable securities at June 30, 2016:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Corporate bonds	$	103,494	$	136	$	(42	)	$	103,588
Governmental bonds	$	8,020	$	7	$	(6	)	$	8,021

	$	111,514	$	143	$	(48	)	$	111,609

Schedule of Amortized Cost of Available-For-Sale Marketable Securities

The amortized cost of available-for-sale marketable securities at December 31, 2016, by contractual maturities, is shown below:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Due in one year or less	$	74,511	$	20	$	(66	)	$	74,465
Due after one year to two years	$	44,439	$	3	$	(180	)	$	44,262

	$	118,950	$	23	$	(246	)	$	118,727

The amortized cost of available-for-sale marketable securities at June 30, 2016, by contractual maturities, is shown below:

	Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair value

Due in one year or less	$	59,124	$	50	$	(11	)	$	59,163
Due after one year to two years	$	52,390	$	93	$	(37	)	$	52,446

	$	111,514	$	143	$	(48	)	$	111,609

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

Schedule of Assets and Liabilities Measured at Fair Value

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Measurements Tables

The following table sets forth the Company’s assets that were measured at fair value as of December 31, 2016 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	December 31, 2016		Level 1		Level 2		Level 3

Cash equivalents:
Money market mutual funds	$	6,510	$	6,510		-		-

Derivative instruments asset	$	19		-	$	19		-

Short-term marketable securities:
Corporate bonds	$	71,719		-	$	71,719		-
Governmental bonds	$	2,746		-	$	2,746		-

Long-term marketable securities:
Corporate bonds	$	39,279		-	$	39,279		-
Governmental bonds	$	4,983		-	$	4,983		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2016 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2016		Level 1		Level 2		Level 3

Cash equivalents:
Money market mutual funds	$	13,373	$	13,373		-		-

Derivative instruments asset	$	481		-	$	481		-

Short-term marketable securities:
Corporate bonds	$	57,158		-	$	57,158		-
Governmental bonds	$	2,005		-	$	2,005		-

Long-term marketable securities:
Corporate bonds	$	46,430		-	$	46,430		-
Governmental bonds	$	6,016		-	$	6,016		-

The following table sets forth the Company’s assets that were measured at fair value as of June 30, 2015 by level within the fair value hierarchy:

	Balance as of		Fair value measurements
Description	June 30, 2015		Level 1		Level 2		Level 3

Derivative instruments asset	$	859		-	$	859		-

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

PREPAID EXPENSES AND OTHER ACCOUNTS RECEIVABLE (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of prepaid expenses and other accounts receivable

	December 31,		June 30,
	2016		2016		2015

Vendor non-trade receivables (*)	$	15,209	$	15,375	$	24,814
Government authorities		2,585		2,727		3,729
OCS		-		-		249
Prepaid expenses and other		3,534		2,756		2,994
Foreign currency derivative contracts		19		482		859

	$	21,347	$	21,340	$	32,645

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of inventories

	December 31,		June 30,
	2016		2016		2015

Raw materials	$	10,053	$	9,805	$	14,405
Finished goods		57,310		71,745		59,545

	$	67,363	$	81,550	$	73,950

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	December 31,		June 30,
	2016		2016		2015

Cost:

Computers and peripheral equipment	$	6,053	$	5,190	$	3,139
Office furniture and equipment		1,505		1,289		779
Laboratory and testing equipment		9,589		8,590		7,205
Machinery and equipment		26,285		18,433		6,936
Leasehold improvements		5,898		5,450		4,047
Vehicles		13		13		13

		49,343		38,965		22,119

Less - accumulated depreciation		13,221		11,134		7,402

Depreciated cost	$	36,122	$	27,831	$	14,717

ACCRUED EXPENSES AND OTHER ACCOUNTS PAYABLE (Tables)

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

Schedule of accrued expenses and other accounts payable

	December 31,		June 30,
	2016		2016		2015

Accrued expenses	$	4,209	$	5,615	$	4,735
Government authorities		1,568		1,406		536
Provision for contractual inventory purchase obligations *		2,009		2,834		1,304
Other		862		870		412

	$	8,648	$	10,725	$	6,987

See also Note 14e.

WARRANTY OBLIGATIONS (Tables)

12 Months Ended

Dec. 31, 2016

Product Warranties Disclosures [Abstract]

Schedule of warranty obligations

	December 31,			June 30,
	2016			2016			2015

Balance, at beginning of year	$	51,192		$	31,879		$	18,181
Additions and adjustments to cost of revenues		13,749			28,848			19,407
Usage and current warranty expenses		(6,566	)		(9,535	)		(5,709	)

Balance, at end of year		58,375			51,192			31,879
Less current portion		(13,616	)		(14,114	)		(9,431	)

Long term portion	$	44,759		$	37,078		$	22,448

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)

12 Months Ended

Dec. 31, 2016

Accumulated Other Comprehensive Income Loss Tables

Schedule of Changes in AOCI

The following table summarizes the changes in accumulated balances of other comprehensive income (loss), net of taxes, for the six months ended December 31, 2016:

	Unrealized gains (losses) on available-for-sale marketable securities			Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total

Beginning balance	$	57		$	243		$	(29	)	$	271
Other comprehensive income (loss) before reclassifications		(193	)		93			(178	)		(278	)
Losses (gains) reclassified from accumulated other comprehensive income (loss)		-			(317	)		-			(317	)
Net current period other comprehensive income (loss)		(193	)		(224	)		(178	)		(595	)

Ending balance	$	(136	)	$	19		$	(207	)	$	(324	)

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the year ended June 30, 2016:

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges			Unrealized gains (losses) on foreign currency translation			Total

Beginning balance	$	-	$	-		$	(222	)	$	(222	)
Other comprehensive income (loss) before reclassifications		56		412			193			661
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1		(169	)		-			(168	)
Net current period other comprehensive income (loss)		57		243			193			493

Ending balance	$	57	$	243		$	(29	)	$	271

The following table summarizes the changes in accumulated balances of other comprehensive loss, net of taxes, for the year ended June 30, 2015:

	Unrealized gains (losses) on available-for-sale marketable securities		Unrealized gains (losses) on cash flow hedges		Unrealized gains (losses) on foreign currency translation			Total

Beginning balance	$	-	$	-	$	(61	)	$	(61	)
Other comprehensive income (loss) before reclassifications		-		-		(161	)		(161	)
Losses (gains) reclassified from accumulated other comprehensive income (loss)		-		-		-			-
Net current period other comprehensive income (loss)		-		-		(161	)		(161	)

Ending balance	$	-	$	-	$	(222	)	$	(222	)

Schedule of Reclassifications out of AOCI

Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statements of Operations
	Six months ended
	December 31, 2016

Unrealized gains (losses) on cash flow hedges	$	47		Cost of revenues
		227		Research and development
		58		Sales and marketing
		46		General and administrative

		378		Total, before income taxes

		(61	)	Income tax expense (benefit)

	$	317		Total, net of income taxes

Unrealized gains (losses) on available-for-sale marketable securities	$	-		Financial income, net
		-		Income tax expense (benefit)

	$	-		Total, net of income taxes

	$	317		Total, net of income taxes

Details about Accumulated Other Comprehensive Income (Loss) Components	Amount Reclassified from Accumulated Other Comprehensive Income (Loss)			Affected Line Item in the Statements of Operations
	Year ended
	June 30, 2016

Unrealized gains (losses) on cash flow hedges	$	30		Cost of revenues
		115		Research and development
		33		Sales and marketing
		24		General and administrative

		202		Total, before income taxes

		(33	)	Income tax expense (benefit)

	$	169		Total, net of income taxes

Unrealized gains (losses) on available-for-sale marketable securities	$	(1	)	Financial income, net
		-		Income tax expense (benefit)

	$	(1	)	Total, net of income taxes

	$	168		Total, net of income taxes

DERIVATIVE INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2016

Derivative Instruments Tables

Schedule of Derivative Instruments

	As of December 31,		As of June 30,
	2016		2016			2015

Derivative assets:
Derivatives not designated as cash flow hedging instruments:
Foreign exchange option contracts	$	-	$	214		$	-
Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts		19		290			-

Total	$	19	$	504		$	-

Derivative liabilities:
Derivatives not designated as cash flow hedging instruments:
Foreign exchange option contracts	$	-	$	(23	)	$	-

Total	$	-	$	(23	)	$	-

Schedule of Change in Unrealized Gains (Losses)

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts	$	93	$	412	$	-	$	-

Total	$	93	$	412	$	-	$	-

Schedule of Net Gains (Losses) Reclassified

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015		2014

Derivatives designated as cash flow hedging instruments:
Foreign exchange forward contracts	$	(317	)	$	(169	)	$	-	$	-

Total	$	(317	)	$	(169	)	$	-	$	-

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41678-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of future minimum lease commitments

2017	$	3,151
2018		2,561
2019		2,231
2020		1,698
2021		1,538
2022 and thereafter		4,466

	$	15,645

CONVERTIBLE PREFERRED STOCK (Tables)

12 Months Ended

Dec. 31, 2016

Temporary Equity Disclosure [Abstract]

Schedule of composition of convertible preferred stock

	Authorized						Issued and outstanding
	Number of shares
	December 31,		June 30,				December 31,		June 30,
	2016		2016		2015		2016		2016		2015

Stock of $0.0001 par value:
Preferred stock		95,000,000		95,000,000		95,000,000		-		-		-

Schedule of convertible preferred stock outstanding prior to consummation of IPO

	Shares outstanding		Number of shares of Common Stock issued upon conversion

Series A Preferred stock		15,558,830		5,186,276
Series B Preferred stock		18,760,196		6,253,398
Series C Preferred stock		15,984,655		5,328,217
Series D Preferred stock		16,024,251		5,341,416
Series D-1 Preferred stock		2,165,441		721,813
Series D-2 Preferred stock		2,598,528		866,175
Series D-3 Preferred stock		4,330,872		1,443,623
Series E Preferred stock		9,321,019		3,107,005
		84,743,792		28,247,923

STOCK CAPITAL (Tables)

12 Months Ended

Dec. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of the activity in the share options granted to employees and members of the board of directors

A summary of the activity in the share options granted to employees and members of the board of directors for the six months ended December 31, 2016 and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2016		4,837,364			4.50		6.58		74,292
Granted		197,821			16.79
Exercised		(133,666	)		2.54
Forfeited or expired		(37,050	)		4.94
Outstanding as of December 31, 2016		4,864,469			5.05		6.24		39,585

Vested and expected to vest as of December 31, 2016		4,741,728			4.97		6.21		38,853

Exercisable as of December 31, 2016		3,388,429			3.50		5.42		31,105

A summary of the activity in the share options granted to employees and members of the board of directors for the year ended June 30, 2016 and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2015		6,034,782		$	3.14		7.06	$	200,438
Granted		238,400			24.92
Exercised		(1,379,668	)		2.07
Forfeited or expired		(56,150	)		4.03
Outstanding as of June 30, 2016		4,837,364		$	4.50		6.58	$	74,292

Vested and expected to vest as of June 30, 2016		4,673,944		$	4.42		6.54	$	72,114

Exercisable as of June 30, 2016		3,146,546		$	3.10		5.63	$	52,141

A summary of the activity in the share options granted to employees and members of the board of directors for the year ended June 30, 2015 and related information follows:

						Weighted
						average
				Weighted		remaining
	Number			average		contractual		Aggregate
	of			exercise		term		intrinsic
	options			price		in years		Value

Outstanding as of July 1, 2014		4,007,116		$	2.13		6.82	$	6,384
Granted		2,116,123		$	5.05
Exercised		(31,981	)	$	2.36
Forfeited or expired		(56,476	)	$	3.42
Outstanding as of June 30, 2015		6,034,782		$	3.14		7.06	$	200,438

Vested and expected to vest as of June 30, 2015		5,742,327		$	3.08		6.97	$	191,067

Exercisable as of June 30, 2015		3,551,239		$	2.17		5.71	$	121,373

Schedule of recognized stock-based compensation expenses

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Cost of revenues	$	871	$	945	$	442	$	108
Research and development, net		2,061		2,364		635		397
Selling and marketing		1,852		2,915		809		297
General and administrative		1,816		2,820		1,070		280

Total stock-based compensation expense	$	6,600	$	9,044	$	2,956	$	1,082

Schedule of composition of common stock capital

	Authorized						Issued and outstanding
	Number of shares
	December 31,		June 30,				December 31,		June 30,
	2016		2016		2015		2016		2016		2015

Stock of $0.0001 par value:
Common stock		125,000,000		125,000,000		125,000,000		41,259,391		40,889,922		39,297,539

Schedule of RSU Activity

A summary of the activity in the RSUs granted to employees and members of the board of directors for the six months ended December 31, 2016, is as follows:

	No. of RSUs			Weighted average grant date fair value
Unvested as of July 1, 2016		834,186			24.74
Granted		874,032			15.74
Vested		(143,303	)		22.01
Forfeited		(49,897	)		24.11
Unvested as of December 31, 2016		1,515,018			19.74

A summary of the activity in the RSUs granted to employees and members of the board of directors for the year ended June 30, 2016, is as follows:

	No. of RSUs			Weighted average grant date fair value
Unvested as of July 1, 2015		67,440			25.09
Granted		981,321			24.77
Vested		(161,173	)		24.36
Forfeited		(53,402	)		18.46
Unvested as of June 30, 2016		834,186			24.74

A summary of the activity in the RSUs granted to employees and members of the board of directors for the year ended June 30, 2015, is as follows:

	No. of RSUs		Weighted average grant date fair value
Unvested as of July 1, 2014		-		-
Granted		67,440		25.09
Vested		-		-
Forfeited		-		-
Unvested as of June 30, 2015		67,440		25.09

Employee Stock Option [Member] | Employees and Members of Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of exercise price range of options

The options outstanding as of December 31, 2016, have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	December 31,		contractual		December 31,		contractual
price	2016		Life in years		2016		Life in years
$0.87 - $1.50		677,625		2.14		677,625		2.14
$1.68 - $2.46		1,340,663		4.71		1,338,271		4.71
$3.03 - $3.96		482,216		7.03		330,770		7.00
$5.01		1,901,081		7.90		945,130		7.90
$9.36		26,663		8.08		12,775		8.08
$15.34		39,000		9.73		2,436		9.73
$17.14		158,821		9.65		9,922		9.65
$20.81		9,600		9.40		-		-
$25.09		228,800		8.64		71,500		8.64

		4,864,469		6.24		3,388,429		5.42

The options outstanding as of June 30, 2016, have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	June 30,		contractual		June 30,		contractual
price	2016		Life in years		2016		Life in years
$0.87 - $1.50		707,091		2.65		707,091		2.65
$1.68 - $2.46		1,411,951		5.22		1,381,725		5.20
$3.03 - $3.96		514,489		7.55		287,763		7.52
$5.01		1,933,216		8.42		715,300		8.41
$9.36		32,217		8.44		11,767		8.19
$20.81		9,600		9.91		-		-
$25.09		228,800		9.14		42,900		9.14

		4,837,364		6.58		3,146,546		5.63

The options outstanding as of June 30, 2015, have been separated into exercise price ranges as follows:

	Options		Weighted		Options		Weighted
	outstanding		average		exercisable		average
Range of	as of		remaining		as of		remaining
exercise	June 30,		contractual		June 30,		contractual
price	2015		Life in years		2015		Life in years

$0.87		490,165		3.14		490,165		3.14
$1.50 - $1.68		771,321		4.04		771,321		4.04
$2.01 - $2.46		2,075,550		6.30		1,794,228		6.24
$3.03 - $3.96		668,270		8.54		247,767		8.46
$5.01		1,996,148		9.42		247,758		9.40
$9.36		33,328		9.59		-		-

		6,034,782		7.08		3,551,239		5.71

Employee Stock Option [Member] | Nonemployee Consultants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of exercise price range of options

The Company has granted options to purchase common shares and RSU’s to non-employee consultants as of December 31, 2016 as follows:

	Options & RSU’s
	outstanding				Exercisable
	as of				as of
Issuance	December 31,		Exercise		December 31,		Exercisable
Date	2016		price		2016		Through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		5,166	October 24, 2022
January 23, 2013		3,333		3.03		3,333	January 23, 2023
January 27, 2014		4,148		3.51		2,552	January 27, 2024
May 1, 2014		3,250		3.51		1,542	May 1, 2024
September 17, 2014		10,830		3.96		6,823	September 17, 2024
October 29, 2014		5,638		5.01		1,860	October 29, 2024
August 19, 2015		17,699		0.00		-
November 8, 2015		2,491		0.00		-
April 18, 2016		2,084		0.00		-
July 11, 2016		2,667		0.00		-
September 21, 2016		4,000		15.34		250	September 21, 2026
September 21, 2016		6,563		0.00		-

		101,202				54,859

The Company has granted options to purchase common shares and RSU’s to non-employee consultants as of June 30, 2016 as follows:

	Options & RSU’s
	outstanding				Exercisable
	as of				as of
Issuance	June 30,		Exercise		June 30,		Exercisable
Date	2016		price		2016		Through
July 31, 2008		33,333		0.87		33,333	July 31, 2018
October 24, 2012		5,166		2.46		4,749	October 24, 2022
January 23, 2013		3,333		3.03		2,986	January 23, 2023
January 27, 2014		4,248		3.51		2,069	January 27, 2024
May 1, 2014		6,000		3.51		3,542	May 1, 2024
September 17, 2014		10,830		3.96		5,466	September 17, 2024
October 29, 2014		5,638		5.01		1,192	October 29, 2024
August 19, 2015		21,501		0.00		-
November 8, 2015		4,167		0.00		-
April 18, 2016		2,500		0.00		-

		96,716				53,337

The Company has granted options to purchase common shares to non-employee consultants as of June 30, 2015 as follows:

	Options
	outstanding				Exercisable
	as of				as of
Issuance	June 30,		Exercise		June 30,		Exercisable
Date	2015		price		2015		Through

July 31, 2008		33,333	$	0.87		33,333	July 31, 2018
January 26, 2011		5,000	$	2.01		5,000	January 26, 2021
January 26, 2012		33,333	$	2.46		33,333	January 26, 2022
October 24, 2012		6,666	$	2.46		4,583	October 24, 2022
January 23, 2013		3,333	$	3.03		2,153	January 23, 2023
January 27, 2014		4,998	$	3.51		1,652	January 27, 2024
May 1, 2014		6,000	$	3.51		2,042	May 1, 2024
September 17, 2014		19,163	$	3.96		3,662	September 17, 2024
October 29, 2014		6,668	$	5.01		890	October 29, 2024

		118,494				86,648

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Schedule of deferred tax liabilities and assets

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

	December 31,		June 30,
	2016		2016		2015

Assets in respect of:

Carryforward tax losses	$	-	$	4,186	$	23,033
Research and Development carryforward expenses- temporary differences		908		743		5,173
Other reserves		1,907		1,367		1,346

		2,815		6,296		29,552

Valuation allowance (1)		-		-		(29,552	)

Deferred tax assets, net	$	2,815	$	6,296	$	-

Schedule of income (loss) before taxes

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015

Domestic	$	3,165	$	3,758	$	2,830
Foreign		27,433		68,472		20,246

	$	30,598	$	72,230	$	23,076

Schedule of taxes on income

	Six months ended December 31,		Year ended June 30,
	2016		2016			2015		2014
Domestic taxes:
Current		1,047		1,737			1,655		100
Deferred		507		(1,380	)		-		-
Foreign taxes:
Current		518		263			300		120
Deferred		3,145		(4,999	)		-		-

	$	5,217	$	(4,379	)	$	1,955	$	220

Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit)

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015			2014

Income (loss) before taxes, as reported in the consolidated statements of operations	$	30,598		$	72,230		$	23,076		$	(21,158	)

Statutory tax rate		34	%		34	%		35	%		35	%
Theoretical tax benefits on the above amount at the US statutory tax rate		10,403			24,558			8,077			(7,405	)
Income tax at rate other than the U.S. statutory tax rate		(5,396	)		(30,229	)		(9,305	)		9,172
Impact of Israel corporate tax rate change		-			-			-			(2,103	)
Non-deductible expenses		164			1,514			3,003			467
Other individually immaterial income tax items		46			(222	)		180			89

Actual tax expense (tax benefit)	$	5,217		$	(4,379	)	$	1,955		$	220

FINANCIAL EXPENSES (INCOME), NET (Tables)

12 Months Ended

Dec. 31, 2016

Nonoperating Income (Expense) [Abstract]

Schedule of financial expenses (income), net

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015			2014

Remeasurement of warrants to purchase convertible preferred stock	$	-		$	-		$	5,350		$	(53	)
Interest on term loan		-			-			579			1,475
Other financial expenses related to term loan		-			-			373			31
Expenses (income) related to hedging transaction		87			136			(1,721	)		189
Interest on short- term loan		-			-			316			537
Interest on marketable securities		(1,504	)		(1,112	)		-			-
Amortization of marketable securities premium and accretion of discount, net		685			532			-			-
Exchange rate loss (income), net, bank charges and other finance expenses		3,521			(27	)		180			608

	$	2,789		$	(471	)	$	5,077		$	2,787

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Summary of revenues within geographic areas

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Revenues based on Customers’ location:
United States	$	160,321	$	334,260	$	238,340	$	64,607
Germany		11,076		22,207		13,290		15,133
Europe (*)		49,523		89,000		52,163		38,655
Rest of the World		19,077		44,376		21,285		14,822
Total revenues	$	239,997	$	489,843	$	325,078	$	133,217

(*) Except for Germany

Schedule of major customers data as percentage of total revenues

	Six months ended December 31,			Year ended June 30,
	2016			2016			2015			2014

Customer A		11.2	%		11.6	%		4.9	%		1.8	%
Customer B		8.7	%		10.9	%		24.6	%		19.1	%
Customer C		8.4	%		10.1	%		5.4	%		3.1	%

Summary of revenues by product family

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015		2014

Inverters	$	112,585	$	223,756	$	156,984	$	62,085
Optimizers		115,229		244,852		158,513		65,018
Others		12,183		21,235		9,581		6,114
Total revenues	$	239,997	$	489,843	$	325,078	$	133,217

Schedule of long-lived assets by geographic region

	Six months ended December 31,		Year ended June 30,
	2016		2016		2015

Israel	$	35,055	$	26,751	$	14,136
U.S.		515		518		342
Europe		466		508		230
Other		86		54		9

Total long-lived assets*	$	36,122	$	27,831	$	14,717

Long-lived assets are comprised of property and equipment, net (marketable securities, prepaid expenses and lease deposits, intangible assets and deferred tax assets are not included).

TRANSITION PERIOD COMPARATIVE DATA (Tables)

12 Months Ended

Dec. 31, 2016

Transition Period Comparative Data Tables

Summary of Financial information

	Six months ended December 31,
	2016		2015
			(Unaudited)

Revenues	$	239,997	$	239,886
Cost of revenues		159,097		167,777

Gross profit		80,900		72,109

Operating expenses:

Research and development, net		20,279		15,290
Sales and marketing		20,444		17,077
General and administrative		6,790		5,606

Total operating expenses		47,513		37,973

Operating income		33,387		34,136

Financial expenses, net		2,789		1,031

Income before taxes on income		30,598		33,105

Taxes on income (tax benefit)		5,217		(5,432	)

Net income	$	25,381	$	38,537

Net basic earnings per share of common stock	$	0.62	$	0.98

Net diluted earnings per share of common stock	$	0.58	$	0.87

Weighted average number of shares used in computing net basic earnings per share of common stock		41,026,926		39,406,797

Weighted average number of shares used in computing net diluted earnings per share of common stock		43,839,342		44,231,660

GENERAL (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
GENERAL (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 17, 2015
Organization Consolidation and Presentation of Financial Statements [Line Items]
Number of shares of common stock sold to the public	8,050,000
Number of shares of common stock sold pursuant to the full exercise of an overallotment option granted to the underwriters	1,050,000
Aggregate net proceeds received from offerings	$ 131,208
Convertible preferred stock converted into number of shares of common stock	28,247,923
Warrants to purchase number of shares of common stock	187,671				187,671
Amount of trade receivables offset against accounts payable		$ 2,008
Lender Concentration Risk [Member] \| Accounts Payable [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Percentage of customer revenue		61.00%	69.00%	79.00%
Customer Concentration Risk [Member] \| Sales Revenue, Net [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Percentage of customer revenue		11.20%	32.50%	24.60%

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) € in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016 USD ($) shares	Jun. 30, 2016 USD ($) shares	Jun. 30, 2015 USD ($) shares	Jun. 30, 2014 USD ($) shares	Jun. 30, 2016 EUR (€)
Financial statements in U.S. dollars
Accumulated other comprehensive loss related to foreign currency translation adjustments, net	$ 207	$ 29	$ 222
Basic and Diluted Net Earnings (Loss) Per Share
Total weighted average number of shares related to the outstanding stock options, convertible preferred stock and warrants to purchase convertible preferred stock, excluded from the calculation of diluted net earnings (loss) per share due to their anti-dilutive effect \| shares	374,156	16,208	20,565,747	25,234,818
Severance pay
Severance expenses	$ 1,131	$ 1,761	$ 1,273	$ 1,109
Shipping and handling costs
Shipping and handling costs	$ 8,131	21,922	26,931	14,066
Warranty obligations
Minimum term of warranty obligations for inverters	12 years
Minimum term of warranty obligations for power optimizers	25 years
Maximum extended product warranty period	25 years
Government grants
Government grants received			763	$ 275
Derivative financial instruments
Derivative instruments	5,098	17,693
Derivative assets	19	504
Derivative liability		$ 23
Euro Member Countries, Euro
Derivative financial instruments
Derivative instruments \| €					€ 30,000

SIGNIFICANT ACCOUNTING POLICIES (Net Earnings (Loss) Per Share) (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net income (loss)	$ 25,381	$ 38,537	$ 76,609	$ 21,121	$ (21,378)
Dividends accumulated for the period				(17,550)
Net income (loss) available to shareholders of common stock	$ 25,381		$ 76,609	$ 3,571	$ (21,378)
Denominator:
Shares used in computing net earnings (loss) per share of common stock, basic (in shares)	41,026,926	39,406,797	39,987,935	11,902,911	2,798,894
Numerator:
Net income (loss)	$ 25,381	$ 38,537	$ 76,609	$ 21,121	$ (21,378)
Dividends accumulated for the period				(16,971)
Net income (loss) available to shareholders of common stock	$ 25,381		$ 76,609	$ 4,150	$ (21,378)
Denominator:
Shares used in computing net earnings per share of common stock, basic	41,026,926	39,406,797	39,987,935	11,902,911	2,798,894
Effect of stock-based awards	2,812,416		4,388,140	3,366,537
Shares used in computing net earnings (loss) per share of common stock, diluted	43,839,342	44,231,660	44,376,075	15,269,448	2,798,894

SIGNIFICANT ACCOUNTING POLICIES (Estimated Useful Lives of Property and Equipment) (Details)	6 Months Ended
	Dec. 31, 2016
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	33.00%
Computer Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	20.00%
Computer Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	33.00%
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	7.00%
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	7.00%
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	15.00%
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	20.00%
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	7.00%
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	33.00%
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	15.00%
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciation rate	15.00%

SIGNIFICANT ACCOUNTING POLICIES (Concentrations of Credit risks) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Concentration Risk [Line Items]
Accrued allowance for doubtful accounts	$ 226	$ 235	$ 13
Rebate accrual	9,089	4,294	$ 659
Amortized cost	118,950	111,514
Fair value	118,727	111,609
Net unrealized gain (loss)	$ (223)	$ 95
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Percentage of customer revenue	20.20%	34.40%	30.00%

SIGNIFICANT ACCOUNTING POLICIES (Estimate Fair Value of Stock Options and Warrants) (Details)	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Employee Stock Option [Member] \| Employee and Executive Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected term (in years)	6 years 22 days
Estimated forfeiture rate	0.00%	10.30%		14.00%
Employee Stock Option [Member] \| Nonemployee Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%	0.00%
Employee Stock Option [Member] \| Minimum [Member] \| Employee and Executive Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	1.28%	1.39%	1.39%	1.62%
Volatility rate	55.33%	55.45%	46.50%	46.30%
Expected term (in years)		5 years 6 months	5 years 6 months	6 years 7 days
Estimated forfeiture rate			12.50%
Employee Stock Option [Member] \| Minimum [Member] \| Nonemployee Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	1.16%	1.15%	1.59%	2.26%
Volatility rate	55.33%	55.37%	45.50%	45.00%
Expected term (in years)	6 years	6 years 4 months 24 days	7 years 4 months 24 days	8 years 3 months 18 days
Employee Stock Option [Member] \| Maximum [Member] \| Employee and Executive Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	1.34%	1.97%	2.06%	1.94%
Volatility rate	55.34%	56.03%	55.10%	55.80%
Expected term (in years)		6 years 1 month 10 days	6 years 3 months 7 days	6 years 3 months 7 days
Estimated forfeiture rate			18.70%
Employee Stock Option [Member] \| Maximum [Member] \| Nonemployee Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	2.45%	2.21%	2.58%	2.75%
Volatility rate	58.57%	55.75%	56.20%	55.80%
Expected term (in years)	10 years	10 years	10 years	10 years
Employee Stock Purchase Plan [Member] \| Employee and Executive Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	0.60%	0.40%
Dividend yield	0.00%	0.00%
Volatility rate	48.08%	62.84%
Expected term (in years)	6 months	6 months
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate				0.09%
Dividend yield				0.00%
Volatility rate				45.00%
Expected term (in years)				1 year 2 months 16 days

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Change in Fair Value of Warrants) (Details) - USD ($)
$ in Thousands

6 Months Ended

12 Months Ended

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2014

Jun. 17, 2015

Mar. 31, 2015

Change in fair value of warrants to purchase convertible preferred stock

Balance at beginning of period

$ 765

$ 818

Issuance of warrants to purchase preferred stock

Exercise of warrants to purchase common stock

^[1]

(6,115)

Change in fair value

5,350

(53)

Balance at end of period

$ 765

Warrants to purchase number of shares of common stock

187,671

Cashless warrants exercised into common shares

154,768

[1]	Upon the closing of the IPO, all outstanding warrants to purchase convertible preferred stock automatically converted into warrants to purchase 187,671 shares of common stock (See Note 1c).

MARKETABLE SECURITIES (Schedule of Available-For-Sale Securities) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Amortized cost	$ 118,950	$ 111,514
Gross unrealized gains	23	143
Gross unrealized losses	(246)	(48)
Fair value	118,727	111,609
Corporate bonds [Member]
Amortized cost	111,188	103,494
Gross unrealized gains	23	136
Gross unrealized losses	(213)	(42)
Fair value	110,998	103,588
Governmental bonds [Member]
Amortized cost	7,762	8,020
Gross unrealized gains		7
Gross unrealized losses	(33)	(6)
Fair value	$ 7,729	$ 8,021

MARKETABLE SECURITIES (Schedule of Contractual Maturities) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Marketable Securities Schedule Of Contractual Maturities Details
Due in one year or less, amortized cost	$ 74,511	$ 59,124
Due in one year or less, gross unrealized gains	20	50
Due in one year or less, gross unrealized losses	(66)	(11)
Due in one year or less, fair value	74,465	59,163
Due after one year to two years, amortized cost	44,439	52,390
Due after one year to two years, gross unrealized gains	3	93
Due after one year to two years, gross unrealized losses	(180)	(37)
Due after one year to two years, fair value	44,262	52,446
Amortized cost	118,950	111,514
Gross unrealized gains	23	143
Gross unrealized losses	(246)	(48)
Fair value	118,727	111,609
Maturities of available-for-sale marketable securities	$ 32,782	$ 6,350

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Money Market Funds [Member]
Fair value of assets	$ 6,510	$ 13,373
Derivative Financial Instruments, Assets [Member]
Fair value of assets	19	481	$ 859
Short-term corporate bonds [Member]
Fair value of assets	71,719	57,158
Short-term governmental bonds [Member]
Fair value of assets	2,746	2,005
Long-term corporate bonds [Member]
Fair value of assets	39,279	46,430
Long-term governmental bonds [Member]
Fair value of assets	4,983	6,016
Level 1 [Member] \| Money Market Funds [Member]
Fair value of assets	6,510	13,373
Level 1 [Member] \| Derivative Financial Instruments, Assets [Member]
Fair value of assets
Level 1 [Member] \| Short-term corporate bonds [Member]
Fair value of assets
Level 1 [Member] \| Short-term governmental bonds [Member]
Fair value of assets
Level 1 [Member] \| Long-term corporate bonds [Member]
Fair value of assets
Level 1 [Member] \| Long-term governmental bonds [Member]
Fair value of assets
Level 2 [Member] \| Money Market Funds [Member]
Fair value of assets
Level 2 [Member] \| Derivative Financial Instruments, Assets [Member]
Fair value of assets	19	481	859
Level 2 [Member] \| Short-term corporate bonds [Member]
Fair value of assets	71,719	57,158
Level 2 [Member] \| Short-term governmental bonds [Member]
Fair value of assets	2,746	2,005
Level 2 [Member] \| Long-term corporate bonds [Member]
Fair value of assets	39,279	46,430
Level 2 [Member] \| Long-term governmental bonds [Member]
Fair value of assets	4,983	6,016
Level 3 [Member] \| Money Market Funds [Member]
Fair value of assets
Level 3 [Member] \| Derivative Financial Instruments, Assets [Member]
Fair value of assets
Level 3 [Member] \| Short-term corporate bonds [Member]
Fair value of assets
Level 3 [Member] \| Short-term governmental bonds [Member]
Fair value of assets
Level 3 [Member] \| Long-term corporate bonds [Member]
Fair value of assets
Level 3 [Member] \| Long-term governmental bonds [Member]
Fair value of assets

PREPAID EXPENSES AND OTHER ACCOUNTS RECEIVABLE (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Vendor non-trade receivables

^[1]

$ 15,209

$ 15,375

$ 24,814

Government authorities

2,585

2,727

3,729

OCS

249

Prepaid expenses and other

3,534

2,756

2,994

Foreign currency derivative contracts

482

859

Prepaid expenses and other accounts receivable

$ 21,347

$ 21,340

$ 32,645

[1]

Vendor non-trade receivables related to contract manufacturers derive from the sale of components to manufacturing vendors who manufacture products for the Company. The Company purchases these components directly from suppliers. The Company does not reflect the sale of these components in revenues (see also Note 14e).

INVENTORIES (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 10,053	$ 9,805	$ 14,405
Finished goods	57,310	71,745	59,545
Inventories	67,363	81,550	73,950
Write-down amount of inventory	$ 113	$ 2,539	$ 992	$ 1,131

PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands

6 Months Ended

12 Months Ended

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2014

Less - accumulated depreciation

$ 49,343

$ 38,965

$ 22,119

13,221

11,134

7,402

Depreciated cost

^[1]

36,122

27,831

14,717

Depreciation expenses

2,702

3,763

2,253

$ 1,978

Purchase of intangible assets

600

800

Patent [Member]

Intangible asset, useful life

Original amount

1,400

800

Accumulated amortization

$ 141

10 years

Amortization of intangible assets

$ 57

Computer Equipment [Member]

Office furniture and equipment [Member]

6,053

5,190

3,139

Laboratory and Testing Equipment [Member]

1,505

1,289

779

Machinery and equipment [Member]

9,589

8,590

7,205

Property in progress under construction and development Cost

26,285

18,433

6,936

10,698

5,519

1,765

Leasehold Improvements [Member]

5,898

5,450

4,047

Vehicles [Member]

Provision for contractual inventory purchase obligations

$ 13

[1]	Long-lived assets are comprised of property and equipment, net (marketable securities, prepaid expenses and lease deposits, intangible assets and deferred tax assets are not included).

ACCRUED EXPENSES AND OTHER ACCOUNTS PAYABLE (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Payables and Accruals [Abstract]

Accrued expenses

$ 4,209

$ 5,615

$ 4,735

Government authorities

1,568

1,406

536

^[1]

2,009

2,834

1,304

Other

862

870

412

Accrued expenses and other accounts payable

$ 8,648

$ 10,725

$ 6,987

[1]	See also Note 14e.

WARRANTY OBLIGATIONS (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
WARRANTY OBLIGATIONS (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Changes in the Company's product warranty liability
Balance, at beginning of year	$ 51,192	$ 31,879	$ 18,181
Additions and adjustments to cost of revenues	13,749	28,848	19,407
Usage and current warranty expenses	(6,566)	(9,535)	(5,709)
Balance, at end of year	58,375	51,192	31,879
Less current portion	(13,616)	(14,114)	(9,431)
Long term portion	$ 44,759	$ 37,078	$ 22,448

TERM LOAN AND WARRANTS TO PURCHASE CONVERTIBLE PREFERRED STOCK (Details) $ / shares in Units, $ in Thousands		6 Months Ended	12 Months Ended
	Dec. 28, 2012 USD ($) $ / shares shares	Dec. 31, 2016 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($) shares	Jun. 30, 2014 USD ($)	Jun. 17, 2015 shares	Mar. 31, 2015 shares
Debt Instrument [Line Items]
Proceeds from loans
Warrants granted to lender \| shares						187,671	187,671
Cashless warrants exercised into common shares \| shares				154,768
Cashless exercise of warrants to purchase common stock				$ 6,115
Term Loan [Member]
Debt Instrument [Line Items]
Loan amount	$ 10,000
Proceeds from loans	10,000
Loan transaction fee paid	$ 100
Debt instrument maturity period	42 months
Interest rate (as a percent)	11.90%
Number of monthly payments in which principal of loan to be paid	33
Warrant intrinsic value threshold	$ 750
Warrant liability at fair value	778				$ 765
Residual amount	9,122
Issuance expense allocated to the warrants liability and to the loan	75
Issuance expenses related to the Warrants liability immediately expensed and recorded as financial expenses, net	6
Issuance expenses related to the Loan recorded as deferred charge assets	$ 69
Term Loan [Member] \| Series D1 Preferred Stock [Member]
Debt Instrument [Line Items]
Warrants granted to lender \| shares	563,014
Exercise price of warrants (in dollars per share) \| $ / shares	$ 2.309
Period after a qualified initial public offering considered while deciding warrants exercisability	12 months

REVOLVING CREDIT LINE (Details) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	1 Months Ended			6 Months Ended
	Feb. 28, 2015	Feb. 17, 2015	Jun. 30, 2011	Dec. 31, 2016
Line of Credit Facility [Line Items]
Aggregate borrowings		$ 40,000	$ 20,000
Maximum specified percentage of eligible trade receivables considered for determining maximum borrowing capacity		80.00%	80.00%
Maximum specified percentage of inventories in transit considered for determining maximum borrowing capacity			65.00%
Maximum [Member]
Line of Credit Facility [Line Items]
Applicable margin (as a percent)	2.00%			2.75%
Minimum [Member]
Line of Credit Facility [Line Items]
Applicable margin (as a percent)	0.50%			0.75%

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Changes in AOCI) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Beginning balance	$ 271	$ (222)	$ (61)
Other comprehensive income (loss) before reclassifications	(278)	661	(161)
Losses (gains) reclassified from accumulated other comprehensive income (loss)	(317)	(168)
Net current period other comprehensive income (loss)	(595)	493	(161)	$ (35)
Ending balance	(324)	271	(222)	(61)
Available-for-sale Securities [Member]
Beginning balance	57
Other comprehensive income (loss) before reclassifications	(193)	56
Losses (gains) reclassified from accumulated other comprehensive income (loss)		1
Net current period other comprehensive income (loss)	(193)	57
Ending balance	(136)	57
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
Beginning balance	243
Other comprehensive income (loss) before reclassifications	93	412
Losses (gains) reclassified from accumulated other comprehensive income (loss)	(317)	(169)
Net current period other comprehensive income (loss)	(224)	243
Ending balance	19	243
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Beginning balance	(29)	(222)	(61)
Other comprehensive income (loss) before reclassifications	(178)	193	(161)
Losses (gains) reclassified from accumulated other comprehensive income (loss)
Net current period other comprehensive income (loss)	(178)	193	(161)
Ending balance	$ (207)	$ (29)	$ (222)	$ (61)

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Reclassifications out of AOCI) (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Cost of revenues	$ 159,097	$ 167,777	$ 337,887	$ 243,295	$ 111,246
Research and development	20,279	15,290	33,231	22,018	18,256
Sales and marketing	20,444	17,077	34,833	24,973	17,792
General and administrative	6,790	5,606	12,133	6,535	4,294
Total, before income taxes	30,598	33,105	72,230	23,076	(21,158)
Income tax expense (benefit)	5,217	(5,432)	(4,379)	1,955	220
Net income (loss)	25,381	38,537	76,609	21,121	(21,378)
Financial income (expenses), net	(2,789)	$ 1,031	471	(5,077)	$ (2,787)
Total, net of income taxes	(317)		(168)
Cash Flow Hedging [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Cost of revenues	47		30
Research and development	227		115
Sales and marketing	58		33
General and administrative	46		24
Total, before income taxes	378		202
Income tax expense (benefit)	(61)		(33)
Net income (loss)	317		169
Available-for-sale Securities [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Financial income (expenses), net			(1)
Income tax expense (benefit)
Total, net of income taxes			(1)
Total, net of income taxes	$ 317		$ 168

DERIVATIVE INSTRUMENTS (Schedule of Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016
Derivative assets	$ 19	$ 504
Derivative liabilities		(23)
Option Contract [Member]
Derivative assets		214
Derivative liabilities		(23)
Forward Contract [Member]
Derivative assets	$ 19	$ 290

DERIVATIVE INSTRUMENTS (Schedule of Change in Unrealized Gains (Losses)) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments Schedule Of Change In Unrealized Gains Losses Details
Derivatives designated as cash flow hedging instruments: Foreign exchange forward contracts	$ 93	$ 412
Total	$ 93	$ 412

DERIVATIVE INSTRUMENTS (Schedule of Net Gains (Losses) Reclassified) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Derivative Instruments Schedule Of Net Gains Losses Reclassified Details
Derivatives designated as cash flow hedging instruments: Foreign exchange forward contracts	$ (317)	$ (169)
Total	(317)	(169)
Expenses (income) related to hedging transaction	$ (87)	$ (136)	$ 1,721	$ (189)

COMMITMENTS AND CONTINGENT LIABILITIES (Schedule of Future Minimum Lease Commitments) (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Future minimum lease commitments
2017	$ 3,151
2018	2,561
2019	2,231
2020	1,698
2021	1,538
2022 and thereafter	4,466
Future minimum lease commitments amount	$ 15,645

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Lease Commitments) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Lease commitments
Contract term	8 years
Rent expenses	$ 1,199	$ 2,238	$ 1,714	$ 1,200

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Guarantees) (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Office Rent Lease Agreements [Member]
Guarantor Obligations [Line Items]
Guarantees amount	$ 617
Customs Transactions [Member]
Guarantor Obligations [Line Items]
Guarantees amount	52
Credit Card Limits [Member]
Guarantor Obligations [Line Items]
Guarantees amount	$ 166

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Contractual Obligations) (Details) - USD ($)
$ in Thousands

6 Months Ended

Apr. 12, 2009

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Royalty commitments

Amount received as royalty grant

$ 703

Royalties payment percentage of gross sales of products developed with funds provided by the BIRD-F

5.00%

Royalties payment subject to maximum percentage of research and development grants

150.00%

Aggregate contingent liability to the BIRD-F amount

$ 1,148

Governmental commitments

Royalties payment percentage to OCS for first three years

4.00%

Royalties percentage of 4% for number of years

3 years

Royalties payment percentage to OCS for thereafter years

4.50%

Maximum royalties percentage of grants received

100.00%

Governmental commitments amount

$ 1,022

Research and development grants received from OCS

990

Accumulated interest

Royal expense realted to OCS grants

260

Contractual purchase obligations

Non-cancelable purchase obligations

65,345

Provision for contractual inventory purchase obligations

^[1]

$ 2,009

$ 2,834

$ 1,304

[1]	See also Note 14e.

LEASE INCENTIVE OBLIGATION (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Leases [Abstract]
Received in cash from the Lessor	$ 2,938
Operating lease receivable	2,345
Operating lease receivable, noncurrent	$ 2,061

CONVERTIBLE PREFERRED STOCK (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Mar. 31, 2015	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 30, 2015
Temporary Equity [Line Items]
Classification of convertible preferred stock temporary equity into stockholders' equity (deficiency)	$ 140,915
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					15,558,830
Number of Shares of Common Stock issued upon conversion					5,186,276
Series B Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					18,760,196
Number of Shares of Common Stock issued upon conversion					6,253,398
Series C Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					15,984,655
Number of Shares of Common Stock issued upon conversion					5,328,217
Series D Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					16,024,251
Number of Shares of Common Stock issued upon conversion					5,341,416
Series D1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					2,165,441
Number of Shares of Common Stock issued upon conversion					721,813
Series D2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					2,598,528
Number of Shares of Common Stock issued upon conversion					866,175
Series D3 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					4,330,872
Number of Shares of Common Stock issued upon conversion					1,443,623
Series E Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Outstanding, Number of shares					9,321,019
Number of Shares of Common Stock issued upon conversion					3,107,005
Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Authorized, Number of shares		95,000,000	95,000,000	95,000,000
Issued, Number of shares
Outstanding, Number of shares					84,743,792
Number of Shares of Common Stock issued upon conversion					28,247,923
Convertible preferred stock, par value		$ 0.0001	$ 0.0001	$ 0.0001

STOCK CAPITAL (Common Stock) (Details)	6 Months Ended
STOCK CAPITAL (Common Stock) (Details)	Dec. 31, 2016 item $ / shares shares	Jun. 30, 2016 $ / shares shares	Jun. 30, 2015 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Reverse stock split ratio	3
Common stock capital
Par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Authorized	125,000,000	125,000,000	125,000,000
Common stock, issued shares	41,259,391	40,889,922	39,297,539
Common stock, outstanding shares	41,259,391	40,889,922	39,297,539
Number of votes per share \| item	1

STOCK CAPITAL (Stock option plans) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance pursuant to stock awards under the plan	10,000,000
Unrecognized compensation expense	$ 36,461
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options available for future grant under the plan	379,358
Employee Stock Option [Member] \| Employees and Members of Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of options exercised	$ 1,790	$ 30,670	$ 484
Weighted average grant date fair values options granted to employees and executive directors	$ 8.86	$ 13.27	$ 4.24	$ 1.98
Employee Stock Option [Member] \| 2015 Global Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance pursuant to stock awards under the plan	3,827,117
Number of options available for future grant under the plan	1,522,068
Percentage of common shares increase automatically each year	5.00%
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock reserved for issuance pursuant to stock awards under the plan	888,569
Number of options available for future grant under the plan	805,250
Number of Common stock purchased	83,319
Period of plan increase automatically number of shares	487,643
Percentage of common shares increase automatically each year	1.00%
Maximum percentage of salary	10.00%
Aggregate limit per participant	$ 10
Purchase price of common stock, percent	85.00%

STOCK CAPITAL (Summary of the activity in the share options) (Details) - Employee Stock Option [Member] - Employees and Members of Board of Directors [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Number of options
Outstanding at the beginning of the period	4,837,364	6,034,782	4,007,116
Granted	197,821	238,400	2,116,123
Exercised	(133,666)	(1,379,668)	(31,981)
Forfeited or expired	(37,050)	(56,150)	(56,476)
Outstanding at the end of the period	4,864,469	4,837,364	6,034,782
Weighted average exercise price
Outstanding at the beginning of the period	$ 4.50	$ 3.14	$ 2.13
Granted	16.79	24.92	5.05
Exercised	2.54	2.07	2.36
Forfeited or expired	4.94	4.03	3.42
Outstanding at the end of the period	$ 5.05	$ 4.50	$ 3.14
Weighted average remaining contractual term in years
Outstanding	6 years 2 months 27 days	6 years 6 months 29 days	7 years 22 days
Aggregate intrinsic Value
Outstanding at the beginning of the period	$ 74,292	$ 200,438	$ 6,384
Outstanding at the end of the period	$ 39,585	$ 74,292	$ 200,438
Vested and expected to vest at the end of the period
Number of options	4,741,728	4,673,944	5,742,327
Weighted average exercise price	$ 4.97	$ 4.42	$ 3.08
Weighted average remaining contractual term in years	6 years 2 months 16 days	6 years 6 months 15 days	6 years 11 months 19 days
Aggregate intrinsic Value	$ 38,853	$ 72,114	$ 191,067
Exercisable at the end of the period
Number of options	3,388,429	3,146,546	3,551,239
Weighted average exercise price	$ 3.50	$ 3.10	$ 2.17
Weighted average remaining contractual term in years	5 years 5 months 1 day	5 years 7 months 17 days	5 years 8 months 16 days
Aggregate intrinsic Value	$ 31,105	$ 52,141	$ 121,373

STOCK CAPITAL (Schedule of exercise price ranges) (Details) - Employees and Members of Board of Directors [Member] - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding	4,864,469	4,837,364	6,034,782
Weighted average remaining contractual Life in years	6 years 2 months 27 days	6 years 6 months 29 days	7 years 29 days
Options exercisable	3,388,429	3,146,546	3,551,239
Weighted average remaining contractual Life in years	5 years 5 months 1 day	5 years 7 months 17 days	5 years 8 months 16 days
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price			$ 0.87
Range of exercise price, lower	$ 0.87	$ 0.87
Range of exercise price, upper	$ 1.50	$ 1.50
Options outstanding	677,625	707,091	490,165
Weighted average remaining contractual Life in years	2 years 1 month 21 days	2 years 7 months 24 days	3 years 1 month 21 days
Options exercisable	677,625	707,091	490,165
Weighted average remaining contractual Life in years	2 years 1 month 21 days	2 years 7 months 24 days	3 years 1 month 21 days
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, lower	$ 1.68	$ 1.68	$ 1.50
Range of exercise price, upper	$ 2.46	$ 2.46	$ 1.68
Options outstanding	1,340,663	1,411,951	771,321
Weighted average remaining contractual Life in years	4 years 8 months 16 days	5 years 2 months 19 days	4 years 15 days
Options exercisable	1,338,271	1,381,725	771,321
Weighted average remaining contractual Life in years	4 years 8 months 16 days	5 years 2 months 12 days	4 years 15 days
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise price, lower	$ 3.03	$ 3.03	$ 2.01
Range of exercise price, upper	$ 3.96	$ 3.96	$ 2.46
Options outstanding	482,216	514,489	2,075,550
Weighted average remaining contractual Life in years	7 years 11 days	7 years 6 months 18 days	6 years 3 months 18 days
Options exercisable	330,770	287,763	1,794,228
Weighted average remaining contractual Life in years	7 years	7 years 6 months 7 days	6 years 2 months 27 days
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price	$ 5.01	$ 5.01
Range of exercise price, lower			$ 3.03
Range of exercise price, upper			$ 3.96
Options outstanding	1,901,081	1,933,216	668,270
Weighted average remaining contractual Life in years	7 years 10 months 24 days	8 years 5 months 1 day	8 years 6 months 15 days
Options exercisable	945,130	715,300	247,767
Weighted average remaining contractual Life in years	7 years 10 months 24 days	8 years 4 months 28 days	8 years 5 months 16 days
Exercise Price Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price	$ 9.36	$ 9.36	$ 5.01
Options outstanding	26,663	32,217	1,996,148
Weighted average remaining contractual Life in years	8 years 29 days	8 years 5 months 9 days	9 years 5 months 1 day
Options exercisable	12,775	11,767	247,758
Weighted average remaining contractual Life in years	8 years 29 days	8 years 2 months 9 days	9 years 4 months 24 days
Exercise Price Range Six [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price	$ 15.34	$ 20.81	$ 9.36
Options outstanding	39,000	9,600	33,328
Weighted average remaining contractual Life in years	9 years 8 months 23 days	9 years 10 months 28 days	9 years 7 months 2 days
Options exercisable	2,436
Weighted average remaining contractual Life in years	9 years 8 months 23 days
Exercise Price Range Seven [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price	$ 17.14	$ 25.09
Options outstanding	158,821	228,800
Weighted average remaining contractual Life in years	9 years 7 months 24 days	9 years 1 month 21 days
Options exercisable	9,922	42,900
Weighted average remaining contractual Life in years	9 years 7 months 24 days	9 years 1 month 21 days
Exercise Price Range Eight [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price	$ 20.81
Options outstanding	9,600
Weighted average remaining contractual Life in years	9 years 4 months 24 days
Options exercisable
Exercise Price Range Nine [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price	$ 25.09
Options outstanding	228,800
Weighted average remaining contractual Life in years	8 years 7 months 21 days
Options exercisable	71,500
Weighted average remaining contractual Life in years	8 years 7 months 21 days

STOCK CAPITAL (Options issued to non-employee consultants) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expenses	$ 6,600	$ 9,044	$ 2,956	$ 1,082
Employee Stock Option [Member] \| Nonemployee Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	101,202	96,716	118,494
Exercisable at the end of the period	54,859	53,337	86,648
Stock compensation expenses	$ 66	$ 524	$ 563	$ 55
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	33,333	33,333	33,333
Exercise price	$ 0.87	$ 0.87	$ 0.87
Exercisable at the end of the period	33,333	33,333	33,333
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	5,166	5,166	5,000
Exercise price	$ 2.46	$ 2.46	$ 2.01
Exercisable at the end of the period	5,166	4,749	5,000
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	3,333	3,333	33,333
Exercise price	$ 3.03	$ 3.03	$ 2.46
Exercisable at the end of the period	3,333	2,986	33,333
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	4,148	4,248	6,666
Exercise price	$ 3.51	$ 3.51	$ 2.46
Exercisable at the end of the period	2,552	2,069	4,583
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	3,250	6,000	3,333
Exercise price	$ 3.51	$ 3.51	$ 3.03
Exercisable at the end of the period	1,542	3,542	2,153
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	10,830	10,830	4,998
Exercise price	$ 3.96	$ 3.96	$ 3.51
Exercisable at the end of the period	6,823	5,466	1,652
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	5,638	5,638	6,000
Exercise price	$ 5.01	$ 5.01	$ 3.51
Exercisable at the end of the period	1,860	1,192	2,042
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	17,699	21,501	19,163
Exercise price	$ 0.00	$ 0.00	$ 3.96
Exercisable at the end of the period			3,662
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	2,491	4,167	6,668
Exercise price	$ 0.00	$ 0.00	$ 5.01
Exercisable at the end of the period			890
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	2,084	2,500
Exercise price	$ 0.00	$ 0.00
Exercisable at the end of the period
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	2,667
Exercise price	$ 0.00
Exercisable at the end of the period
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	4,000
Exercise price	$ 15.34
Exercisable at the end of the period	250
Employee Stock Option [Member] \| Nonemployee Consultants [Member] \| Award Date Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at the end of the period	6,563
Exercise price	$ 0.00
Exercisable at the end of the period

STOCK CAPITAL (Schedule of RSU Activity) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Stock Capital Schedule Of Rsu Activity Details
Unvested at beginning of period	834,186	67,440
Granted	874,032	981,321	67,440
Vested	(143,303)	(161,173)
Forfeited	(49,897)	(53,402)
Unvested at end of period	1,515,018	834,186	67,440
Unvested at beginning of period, grant date fair value	$ 24.74	$ 25.09
Granted	15.74	24.77	25.09
Vested	22.01	24.36
Forfeited	24.11	18.46
Unvested at end of period, grant date fair value	$ 19.74	$ 24.74	$ 25.09

STOCK CAPITAL (Schedule of stock-based compensation expense for employees and non-employee consultants) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 6,600	$ 9,044	$ 2,956	$ 1,082
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	871	945	442	108
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	2,061	2,364	635	397
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	1,852	2,915	809	297
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 1,816	$ 2,820	$ 1,070	$ 280

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Taxes [Line Items]
Corporate tax rate (as a percent)	34.00%	34.00%	35.00%	35.00%
Unrecognized tax benefits	$ 300
Subsidiaries [Member] \| ISRAEL
Income Taxes [Line Items]
Corporate tax rate (as a percent)		25.00%	26.50%	26.50%
Tax exempt profits	$ 26,459
Subsidiaries [Member] \| GERMANY
Income Taxes [Line Items]
Corporate tax rate (as a percent)	33.00%

INCOME TAXES (Schedule of Deferred Tax Liabilities And Assets) (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Assets in respect of:

Carryforward tax losses

$ 4,186

$ 23,033

Research and Development carryforward expenses- temporary differences

908

743

5,173

Other reserves

1,907

1,367

1,346

Deferred tax assets, gross

2,815

6,296

29,552

Valuation allowance

^[1]

(29,552)

Deferred tax assets, net

$ 2,815

$ 6,296

[1]

ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluated the net deferred tax assets for each separate tax entity. As of June 30, 2015, the Company concluded that it is not more likely than not that the net deferred tax assets will be realized and a full valuation allowance has been recorded against these assets. The Company's estimate of future book-taxable income considers available evidence, both positive and negative, about its operating businesses and investments, including an aggregation of individual projections for each significant operating business and investment, estimated apportionment factors for state and local taxing jurisdictions and includes all future years that the Company estimated it would have available net operating loss carryforwards. During fiscal year 2016, the Company determined that the positive evidence outweighs the negative evidence for deferred tax assets and concluded that these deferred tax assets are realizable on a "more likely than not" basis. This determination was mainly due to expected future results of positive operations and earnings history.

INCOME TAXES (Schedule of Income (Loss) Before Taxes) (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Domestic	$ 3,165		$ 3,758	$ 2,830
Foreign	27,433		68,472	20,246
Income (loss) before taxes on income	$ 30,598	$ 33,105	$ 72,230	$ 23,076	$ (21,158)

INCOME TAXES (Schedule of Taxes on Income) (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Domestic taxes:
Current	$ 1,047		$ 1,737	$ 1,655	$ 100
Deferred	507		(1,380)
Foreign taxes:
Current	518		263	300	120
Deferred	3,145		(4,999)
Actual tax expense (tax benefit)	$ 5,217	$ (5,432)	$ (4,379)	$ 1,955	$ 220

INCOME TAXES (Schedule of reconciliation between the theoretical tax expense and the actual tax expense (benefit)) (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income (loss) before taxes, as reported in the consolidated statements of operations	$ 30,598	$ 33,105	$ 72,230	$ 23,076	$ (21,158)
Statutory tax rate	34.00%		34.00%	35.00%	35.00%
Theoretical tax benefits on the above amount at the US statutory tax rate	$ 10,403		$ 24,558	$ 8,077	$ (7,405)
Income tax at rate other than the U.S. statutory tax rate	(5,396)		(30,229)	(9,305)	9,172
Impact of Israel corporate tax rate change					(2,103)
Non-deductible expenses	164		1,514	3,003	467
Other individually immaterial income tax items	46		(222)	180	89
Actual tax expense (tax benefit)	$ 5,217	$ (5,432)	$ (4,379)	$ 1,955	$ 220

FINANCIAL EXPENSES (INCOME), NET (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Nonoperating Income (Expense) [Abstract]
Remeasurement of warrants to purchase convertible preferred stock				$ 5,350	$ (53)
Interest on term loan				579	1,475
Other financial expenses related to term loan				373	31
Expenses (income) related to hedging transaction	87		136	(1,721)	189
Interest on short-term loan				316	537
Interest on marketable securities	(1,504)		(1,112)
Amortization of marketable securities premium and accretion of discount, net	685		532
Exchange rate loss (income), net, bank charges and other finance expenses	3,521		(27)	180	608
Financial expenses (income), net	$ 2,789	$ (1,031)	$ (471)	$ 5,077	$ 2,787

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Summary of Revenues Within Geographic Areas) (Details) - USD ($)
$ in Thousands

6 Months Ended

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Jun. 30, 2016

Jun. 30, 2015

Jun. 30, 2014

Revenues from External Customers and Long-Lived Assets [Line Items]

Revenues from External Customers and Long-Lived Assets [Line Items]

$ 239,997

$ 239,886

$ 489,843

$ 325,078

$ 133,217

UNITED STATES

Revenues from External Customers and Long-Lived Assets [Line Items]

160,321

334,260

238,340

64,607

GERMANY

Revenues from External Customers and Long-Lived Assets [Line Items]

11,076

22,207

13,290

15,133

Europe [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

^[1]

49,523

89,000

52,163

38,655

Others [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

$ 19,077

$ 44,376

$ 21,285

$ 14,822

[1]	Except for Germany

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of Major Customers Data As a Percentage of Total Revenues) (Details) - Sales Revenue, Goods, Net [Member] - Customer Concentration Risk [Member]	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Customer A [Member]
Revenue, Major Customer [Line Items]
Percentage of customer revenue	11.20%	11.60%	4.90%	1.80%
Customer B [Member]
Revenue, Major Customer [Line Items]
Percentage of customer revenue	8.70%	10.90%	24.60%	19.10%
Customer C [Member]
Revenue, Major Customer [Line Items]
Percentage of customer revenue	8.40%	10.10%	5.40%	3.10%

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Summary of Revenues by Product Family) (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Revenue from External Customer [Line Items]
Total revenues	$ 239,997	$ 239,886	$ 489,843	$ 325,078	$ 133,217
Inverters [Member]
Revenue from External Customer [Line Items]
Total revenues	112,585		223,756	156,984	62,085
Optimizers [Member]
Revenue from External Customer [Line Items]
Total revenues	115,229		244,852	158,513	65,018
Other Products [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 12,183		$ 21,235	$ 9,581	$ 6,114

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Schedule of Long-Lived Assets by Geographic Region) (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

Jun. 30, 2016

Jun. 30, 2015

Revenues from External Customers and Long-Lived Assets [Line Items]

^[1]

$ 36,122

$ 27,831

$ 14,717

UNITED STATES

Revenues from External Customers and Long-Lived Assets [Line Items]

515

518

342

Europe [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

466

508

230

ISRAEL

Revenues from External Customers and Long-Lived Assets [Line Items]

35,055

26,751

14,136

Others [Member]